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Message from the Director
Coordinating Center for Infectious Diseases 
On behalf of the Coordinating Center for Infectious Diseases (CCID), I am pleased to present this report 
on infectious disease activity at the Centers for Disease Control and Prevention (CDC). This document 
provides a snapshot of CCID’s budget and highlights many of the policies, programs, and collaborative 
activities that were undertaken in 2008 to advance CDC’s public health mission. 
As the focal point for infectious diseases and microbial threats at CDC, CCID and its four National Centers have made significant progress in 
2008. To highlight just a few accomplishments:
We helped identify threats and quell potential outbreaks ranging from hemorrhagic fevers in Africa to food-borne diseases here at home.  z
We improved our preparedness for an influenza pandemic through planning, exercises, and enhanced relationships with partners and  z
stakeholders. 
We helped achieve a record number of people choosing to be vaccinated for seasonal influenza.  z
Building on our work with avian influenza, we enhanced our relationships with colleagues in veterinary science, environmental science,  z
and agriculture, thereby expanding the concept of “One Health”. 
We continued to reduce U.S. morbidity for common vaccine-preventable diseases through the high coverage rates realized from our  z
vaccination programs. 
We developed an improved method of estimating the onset of HIV, allowing better estimates for the scope and magnitude of the  z
epidemic in the United States. 
Internationally, we provided critical life-sustaining antiretroviral therapy to more than two million persons living with HIV.  z
We continued to enhance our infrastructure and capacity to support science, public health research, and   z
programs, through new state-of-the-art facilities. 
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Director’s Message
Even as we reflect on our significant progress, we realize there is still much more to achieve. With the publication of this retrospective, 
CDC, together with our partners here and abroad continues to respond to the worldwide outbreaks of H1N1 influenza virus. This ongoing 
event provides a stark reminder of the vital work ahead, the importance of continuing our vigilance, and strengthened collective efforts to 
prevent and control infectious disease outbreaks and other public health emergencies. 
Moving forward, other serious challenges continue to impact the public’s health and welfare. Changing ecosystems, population movement, 
and other factors fuel the emergence of new infections and drug-resistant strains of previously treatable ones. Food-borne outbreaks 
remain an ongoing challenge. The successes achieved in virtually eliminating some vaccine-preventable childhood diseases has resulted in 
complacency among some about getting children vaccinated; this couple with the fear of vaccines has provided the opportunity for the re-
emergence of those threats. Healthcare associated infections (HAI) continue to place both patients and healthcare workers at unacceptably 
high levels of risk. Our nation’s economic challenges also have significant implications for protecting the public’s health, particularly those 
who have been disenfranchised. Clearly, there is much more to be done. Looking forward, we are committed to meeting these challenges in 
pursuit of our vision of a world safe from infectious disease and microbial threats. 
I would like to take this opportunity to thank our dedicated CDC professionals who commit their energy and talents every day in support of 
our mission to make a difference in the lives of Americans and people, the world across, through the prevention, detection, and control of 
infectious diseases. I would also like to recognize our many collaborative partners. Without their contributions and commitment, our efforts 
would be neither as far reaching nor as effective.
Mitchell Cohen, MD 
RADM U.S. Public Health Service 
Director, Coordinating Center for Infectious Diseases 
Centers for Disease Control and Prevention





Infectious Diseases  
and the Centers for Disease Control and Prevention 
People and Science in Service of Public Health
The Centers for Disease Control and Prevention (CDC), first known as the Communicable Disease Center, was 
established in Atlanta in 1946. It had evolved from an agency called Malaria Control in War Areas, with a mission to 
combat the spread of this dreaded infectious disease. Much has changed in the world since CDC’s founding. Science 
and technology have advanced exponentially, improving our ability to diagnose and treat a myriad of infectious 
diseases. CDC, with its dedicated people and commitment to science in the service of public health, has been at the 
forefront of these efforts. Today, CDC’s scope and mission have grown to encompass of a multitude of health issues: 
ranging from chronic diseases including diabetes and cancer, environmental health threats and natural disasters, 
injury and disability, to the threat of bioterrorism. Throughout this expansion, the prevention and control of infectious 
diseases and microbial threats remain at the core of CDC’s public health mission, with more than half of the agency 
dedicated to this vital effort.
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Coordinating Center for Infectious Diseases (CCID) 
The axis of CDC’s efforts toward prevention, detection, and control of infectious diseases is the Coordinating Center for 
Infectious Diseases. CCID comprises four national centers with unique and complementary missions and capacities. 
CCID collectively envisions a world safe from infectious diseases and microbial threats, both naturally occurring and 
those that are intentionally spread. 
In support of CDC’s public health mission, CCID strives to protect people from infectious diseases and thereby enhance 
the potential for full, satisfying, and productive living across the lifespan of all people in all communities With CCID 
and its four national centers committed to that end, CDC is known for: 
z Working with state health departments and others to conduct disease surveillance 
z Providing national leadership in times of public health crisis 
z Diagnosing rare, highly dangerous, and previously unknown diseases 
z Responding rapidly to requests for outbreak assistance in the United States and abroad
z Integrating epidemiologic and laboratory expertise to address infectious disease problems
z Researching public health issues and translating the findings into practical tools for disease control and prevention 
z Using surveillance data to drive public health action and inform strategic planning
z Training public health workers in applied epidemiology and state-of-the-art diagnostics
CDC’s commitment to science combined with public health programs, dedicated professionals, and public health 
partners, work to meet the challenges of infectious diseases and microbial threats— from the natural emergence of 
new disease strains to the intentional use of biological agents as weapons of terrorism.
CDC’s unique combination of capabilities, programs, and critical scientific and laboratory infrastructure are a vitally 
important treasure and resource for the protection and promotion of health domestically and globally.
Healthy People in a Healthy World:  
Responding to Infectious Diseases on Global Scale
Every year, infectious diseases are responsible for millions of deaths, untold suffering and hardship that can be 
physical, psychological, and economic.
The risk of regional epidemics and global pandemics is a very real concern facing governments and health workers 
the world over. New, emerging infectious diseases and microbial threats, antimicrobial resistant pathogens, and the 
possibility of pandemic disease—in the form of influenza or another illness—represent just a few examples of how 
infectious diseases pose a real and potentially catastrophic threat to human health everywhere.
Protecting U.S. Health at Home and Abroad. Infectious diseases do not recognize boarders. Therefore, 
safeguarding our nation’s health requires meeting disease challenges both domestically and globally. In partnership 
with other U.S. government agencies and private partners, CDC plays a critical role in protecting the world’s health 




z Manages an annual budget over $6 billion, 87% of which is used for  
extramural programs and activities
z Coordinates efforts across 4 national centers and their 20 divisions
z Is the organizational home for the cross-agency Influenza Coordination Unit (ICU)
z Employs over 5,000 staff in over 50 countries and 170 occupations
z Operates over 30 World Health Organization (WHO) Collaborating Centers
z Operates and oversees the 20 U.S. quarantine stations nationwide
z Responded to more than 90 international disease outbreaks and public health 
events and discovered 22 new pathogens in 2008 alone
z Addresses a wide range of public health issues and activities including
– Surveillance
– Outbreak investigation and response
– Epidemiologic and laboratory research
– Policy development and advocacy 
– Health behavior promotion
– Leadership and training 
At the request of state, local, or foreign governments, or the World Health Organization (WHO), CDC 
provides assistance to areas and people impacted by infectious diseases. 
CDC programs such as those targeting polio eradication, malaria, HIV/AIDS, TB elimination, measles, influenza, 
and other diseases provide ongoing assistance to countries across the globe. Annually, vaccinations are provided to 
millions of infants and children to protect them against preventable diseases and death. 
CDC’s Global Disease Detection and other surveillance networks including those covering Africa, the Americas and 
Caribbean, Asia, Europe, and the Middle East allow CDC to help foreign governments and partners quickly detect and 
contain outbreaks at their source.  Included in these efforts are collaborations at overseas field stations in countries 
such as Kenya, Thailand, and Guatemala.  These programs provide CDC scientists with invaluable opportunities to 
contribute globally and to examine the epidemiology of emerging and other infectious diseases—their agents, 
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lifecycles, communicability, and prevention and control methods.  In addition, CDC works with local health officials 
and other partners to provide training, building important laboratory capacity, infrastructure, and expertise in disease 
surveillance and epidemiology within host nations.
A Vital World Resource. Considered the premiere public health organization in the world, CDC is a vital resource  
to people in need across the globe. Providing international outbreak assistance is recognized as a critical and  
integral function of CDC. 
Important facets of CDC’s infectious diseases capacity are the more than 30 World Health Organization (WHO) 
Collaborating Centers. These are most often housed in laboratories and provide WHO with technical guidance 
including diagnostic and epidemiologic support for numerous infectious disease agents ranging from antimicrobial-
resistant  agents (such as Methicillan Resistant Staphylococcus Aureas—MRSA) to viral hemorrhagic fevers (such as 
Ebola). As WHO does not maintain laboratory resources of its own, the CDC Collaborating Centers are crucial, and for 
many agents, are the only laboratories in the world with the necessary diagnostic capabilities so critical to effective 
prevention and control efforts.
Health Diplomacy. CDC’s efforts in addressing the goals of healthy people in a healthy world go beyond disease 
prevention and control. CDC personnel at field offices and those deployed for targeted responses are ambassadors 
of goodwill and hope—often when people need help the most. By assisting other countries faced with dangerous 
diseases, CDC furthers U.S. humanitarian and diplomatic efforts. These efforts in turn help create goodwill between 
the U.S. and other countries, thus improving international relations and helping advance broader U.S. policy 
objectives.
Maintaining and strengthening CDC’s domestic and global capacities and critical infrastructure are vital to protecting 
the health of Americans and broader national interests, now and into the future.
In the following pages, CCID offers a snapshot of CDC’s infectious disease activities and accomplishments during Fiscal 
Year 2008, toward a vision of a world safe from infectious diseases and microbial threats, made possible through our 










National Center for Immunization and Respiratory Diseases 
(NCIRD)
This Center’s mission focuses on the prevention of disease, disability, and death through immunization and by control 
of respiratory and related diseases. 
Respiratory infectious agents have captured the public spotlight based on their sudden emergence, severe clinical 
consequences, and the difficulty of controlling their spread. Outbreaks of Legionnaires’ Disease, resurgent measles, 
meningococcal C meningitis in colleges, hantavirus acute respiratory syndrome in the Southwestern US, inhalational 
anthrax, severe acute respiratory syndrome—SARS, H5N1 avian influenza, and more recent emergence of severe type 
4 adenovirus collectively provide a vivid picture of the public’s concern, the public health infrastructure under strain, 
and the critical role of astute clinicians and other health workers as the bedrock of our nation’s health protection 
system. For decades, CDC has been known for its role in countering urgent respiratory health threats, based on 
integration of laboratory and epidemiologic scientific expertise, rapid response capability, and support of local and 
state public health programs. More recently, CDC’s expertise in risk communication has been added to the essential 
resources available to address this type of health crisis. 
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While the emergence of new or unrecognized infectious diseases traditionally requires a broad collaboration across 
CDC as well as across state, local, and federal jurisdictions, the formation of NCIRD provided the opportunity to 
strengthen CDC’s approach to preparedness for infectious respiratory threats.
CDC is working on strategies that will improve prevention of and response to seasonal influenza throughout the world, 
in support of the President’s National Strategy on Pandemic Influenza, the Department of Health and Human Services 
Pandemic Influenza Plan, and other initiatives, to ensure that the US is prepared for an influenza pandemic.
In the US, immunization programs are supported by CDC’s infectious disease infrastructure that seeks to advance the 
knowledge base of disease burdens and effective strategies to prevent diseases. Immunization and respiratory disease 
programs, supported by this strong integrated infrastructure, improve national, state, local, and global health capacity 
to respond to outbreaks of vaccine-preventable and other respiratory and related infectious diseases. 
NCIRD People in Action
The National Center for Immunization and Respiratory Diseases completed 2008 with a renewed commitment to 
make a difference. Thanks to the hard work of CDC staff and partners, the collective efforts are paying off.
Protecting Children
Every year in the developing world, nearly 1 million children die from pneumonia and other infections of the lower 
respiratory tract. In addition, new respiratory infections, such as SARS, have demonstrated their ability to travel 
quickly across international borders, creating a larger global threat.
NCIRD epidemiologists and laboratory scientists have been working with CDC partners to build a new overseas 
network of sites that are able to detect, monitor, and prevent severe respiratory diseases using state-of-the-art 
diagnostic methods. CDC investigators traveled to CDC collaborative sites in Bangladesh, China, Egypt, Guatemala, 
Kenya, and Thailand to train site investigators, analyze data, and develop system plans. They also worked with site 
investigators to evaluate where patients with severe respiratory infections seek care and whether those infections 
are identified by the program. In addition, CDC held a Global Disease Detection laboratory workshop that trained 
participants from each site on new diagnostic methods and addressed challenges facing scientists in developing 
countries. Meanwhile, NCIRD continued developing new tests to detect respiratory pathogens and began building a 
bank of respiratory specimens that can be used to develop new diagnostic tests and discover new pathogens. 
NCIRD’s polio eradication efforts contributed to a significant decline in the number of cases worldwide. In particular, 
there were significant achievements in India and Nigeria, two of the four countries (including Afghanistan and 
Pakistan) where indigenous transmission of polio continues. 
Pneumonia and meningitis are major killers of young children in the developing world. For a variety of economic and 
other reasons, vaccines to prevent these diseases are often underutilized or unavailable. In response, NCIRD is working 
with partners around the world to make life-saving vaccines available to those most in need.
Building upon this effort, CDC and its partners worked to develop and deploy systems around the world to support 
the improvement of routine immunization service delivery. In Sierra Leone, for example, CDC worked with its 
partners—the national Ministry of Health, WHO, the U.N. Foundation, and DataDyne—to deploy an integrated 
child-survival data system in every district of the country, and also a PDA-based system to provide data on integrated, 
supportive supervision on the provincial level. Together, these systems aim to provide program managers with timely 
information on routine immunization efforts as well as malaria and diarrheal disease control. 
Immunization Action
To deliver on the promise of the recently recommended vaccines for 11- and 12-year olds – Tdap, meningococcal 
conjugate, and HPV vaccine (for girls) – CDC launched a preteen immunization campaign, funded adolescent 
13
National Centers
coordinators for state programs, and spotlighted new communication materials. Substantial drops in both pneumonia 
hospitalizations and direct medical care costs were reported due to pneumococcal conjugate vaccine use. A record 
number of influenza vaccine doses were distributed for the 2008 season. There were challenges, also, including 
selected vaccine shortages and transitioning more areas to centralized vaccine distribution.
Vaccine Research and Development 
Developing new vaccines is a critical aspect of preparing for new pandemic threats. In collaboration with the 
National Center for Environmental Health, NCIRD has been working to improve its method for testing the potency 
of pandemic and seasonal influenza vaccines, with the aim of greater speed, sensitivity, precision, and accuracy in 
the quantification of influenza hemaglutinin, the component critical for immune response to a vaccine. Other NCIRD 
research is exploring how to create vaccines that offer broader cross-reactive immunity and protection, especially 
for the elderly, as well as how to develop techniques to speed vaccination and extend vaccine supply. For example, 
preliminary results from a study led by CDC and the Walter Reed Army Medical Center indicate that during a vaccine 
shortage, healthcare providers might be able to stretch limited vaccine supply by immunizing healthy adults with a 
half-dose of seasonal influenza vaccine.
Respiratory Disease Response
Together with state, local and international public health counterparts, CDC responded to a new strain of adenovirus 
type 14, and outbreaks of Legionnaires disease, Mycoplasma pneumoniae, pertussis, and pneumococcus. H5N1 
avian influenza sustained its high virulence in human cases. In partnership with the Council of State and Territorial 
Epidemiologists, domestic influenza surveillance was strengthened with strategies that will improve both seasonal 
and pandemic influenza efforts. 
Prevention
Using historical data, CDC tallied the remarkable impact on illness and death that vaccines have had: more than 
99% reductions have occurred for several of the vaccine-preventable diseases assessed. Also, exploration was 
Comparison of 20th Century Average Morbidity and  
Current Annual Morbidity: Vaccine-Preventable Diseases
Disease






Smallpox 29,005 0 100%
Diphtheria 21,053 0 100%
Measles 530,217 132 > 99%
Mumps 162,344 386 > 99%
Pertussis 200,752 386 95%
Polio (paralytic) 16,316 0 100%
Rubella 47,745 17 > 99%
Congenital Rubella Syndrome 152 0 100%
Tetanus 580 15 97%
Haemophilus influenzae 20,000 219* 97%
† Source:  JAMA. 2007;298(18):2155-2163 
†† Source:  CDC.  MMWR January 9, 2009;57(53);1420-1430.  (Provisional, week 53 data) 
* 27 type b and 192 unknown (< 5 years of age)
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continued on the reconstructed 1918 pandemic influenza virus which revealed more clues to the molecular basis of its 
transmissibility and virulence.
Training
Strengthening preparedness was front and center. NCIRD provided pandemic and avian influenza training to 
international staff, rapid response teams, laboratory personnel, Epidemic Intelligence Service Officers, and partners. 
CDC-wide as well as tabletop exercises on pandemic influenza expanded the numbers of CDC staff and other health 
workers familiar with response plans. Strategic planning around CDC’s health protection goals and the agency’s 
immunization and respiratory disease efforts accelerated.
Global Horizons
While vaccine-preventable diseases and respiratory infections know no borders, global cooperation led to new 
milestones. Measles deaths in Africa fell by 90% compared with the 2000 baseline, and continued progress is  
being made in polio eradication. CDC’s global efforts included integrating immunizations with other health service 
delivery, including insecticide-treated nets for malaria control. It is truly an exciting era in immunizations and 
respiratory infectious disease prevention and control. 
Vaccine Management Business Improvement Process
In 2008, all 64 states, cities, and U.S. affiliated jurisdictions that receive federal grants for vaccines—and contribute their 
own funds as well—made the transition to a new centralized vaccine distribution system. This system now uses only two 
warehouses nationwide, as opposed to the 500 used before. With the new system, nationwide vaccine inventory is kept at 
appropriate levels to meet demand. In FY 2008, the one-time saving from this strategy was $80 million.
Quick CDC Response to Local Outbreaks Saves Lives
Investigating an Emerging Pathogen in Alaska
In late September 2008, a physician on Prince of Wales 
Island, Alaska, noticed an unusually large number 
of  pneumonia cases and reported this finding to the 
Alaska Department of Health and Social Services (AK 
DHSS). AK DHSS sent a team to investigate and collect 
respiratory specimens for testing. Preliminary tests 
were negative for the common respiratory pathogens. 
AK DHSS consulted CDC experts and shipped 
specimens to CDC for testing. Two days later, in several 
of the specimens, CDC’s laboratory found adenovirus 
14 (Ad14), a previously rare virus in the United States that caused an outbreak of severe respiratory disease in Oregon in 
2007 and, since then, has been a common cause of illness among U.S. military recruits. 
In response to the Prince of Wales Island outbreak, CDC partnered with AK DHSS to provide investigative, epidemiologic, 
and laboratory support. Preliminary data indicate that 39 patients met the outbreak case definition, of whom 10 were 
hospitalized and 1 died. The community, working with public health providers, also became involved in disseminating 
information about how to prevent further spread of the disease. Their efforts included an extensive hand-washing 
campaign in the schools and throughout the community. 
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CDC Assists State Health Departments with  
Rapid Response to Life-Threatening Resistant Organisms
Drug-resistant Strain of Bacterial Meningitis
One of every four patients contracting bacterial meningitis dies or has 
permanent disability. Certain drugs have been used successfully to 
treat this disease, if they are administered quickly. Historically, bacterial 
resistance to these drugs has been extremely rare in the U.S.
However, from January 2007 through January 2008, the North Dakota 
Department of Health (NDDH) and the Minnesota Department of 
Health (MDH) detected the first three North American cases of bacterial 
meningitis caused by a drug resistant strain. 
When the third case was confirmed, the two health departments placed 
an urgent request for help to CDC. Within 24 hours, a team of CDC scientists arrived at the North Dakota-Minnesota 
border region where the cases occurred. Working with state and local officials the CDC team played critical roles in the 
epidemiologic investigation—including obtaining more than 500 throat cultures to assess circulation of the resistant 
strain. CDC’s Meningitis Reference Laboratory provided further confirmation that the three cases were caused by an 
identical strain and further analyzed the resistance mechanism.
The timely investigation by local, state, and CDC public health staff resulted in revised preventation recommendations for 
the local area that were published and disseminated only weeks after the third case. To monitor the threat of increased 
resistance, CDC has worked to enhance routine surveillance for resistant strains and is continuing to collaborate with state 
health departments to perform routine testing in 15 additional states.
CDC Scientists Respond to Pandemic Influenza Threats
Over the last several years, the highly pathogenic avian influenza A 
(H5N1) virus—one strain of bird flu—has spread to birds in Asia, 
Africa and Europe. Some of those birds have passed the virus on to 
humans. Of the few avian flu viruses that have crossed the species 
barrier to infect humans, H5N1 has caused the largest number 
of detected cases of severe disease and death. From late 2003 
through December 2008, the virus caused nearly 400 laboratory-
confirmed human infections; more than 60 percent of those 
infected have died. Most people were infected after coming into close contact with infected birds, but health experts 
worry that these viruses could develop the ability to spread easily among humans, creating the potential for a pandemic.
In response to this threat, CDC researchers recently collaborated on testing an experimental drug as an alternative 
approach to preventing and treating avian flu in humans. The study results were promising. The novel drug (sialidase 
fusion protein) protected 100% of test mice from fatal disease, effectively blocked infection in 70% of them, and 
prevented the virus from spreading to their brains. The study also showed that with early treatment, mice that were 
infected had a better chance for survival—an encouraging finding for potential treatment of humans. Additionally, CDC 
has strengthened capability of more than 100 National Influenza Centers to diagnose seasonal and H5 avian influenza by 
providing diagnostic tools and training.
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National Center for HIV, Hepatitis, STD, and  
TB Prevention (NCHHSTP) 
NCHHSTP’s mission is to maximize public health and safety nationally and internationally through the elimination, 
prevention, and control of disease, disability, and death caused by HIV/AIDS (human immunodeficiency virus/aquired 
immunodeficiency syndrome), non-HIV retroviruses, viral hepatitis, other sexually transmitted diseases (STDs), and TB 
(tuberculosis). NCHHSTP achieves its mission by:
z Developing, implementing, and evaluating effective science-based prevention programs for HIV, viral hepatitis, STDs, and TB;
z Developing high-quality research and translating relevant findings into a prevention policy and programs;
z Creating and strengthening strategic relationships and networks with individuals and organizations;
z Strengthening and promoting surveillance activities and findings for program planning, public health response, and 
evaluation.
NCHHSTP integrates epidemiology, laboratory science, and prevention initiatives related to a broad range of STDs to 
enhance opportunities to develop and implement collaborative public health interventions with at-risk populations. 
NCHHSTP is responsible for public health surveillance, prevention research, and programs to prevent and control HIV 
infection and AIDS, non-HIV retroviruses, other STDs, viral hepatitis, and TB. This center works in collaboration with 
partners at community, state, national, and international levels applying well-integrated, multidisciplinary programs 
of research, surveillance, risk factor and disease intervention, and evaluation. 
These efforts are guided by three over-arching priorities:
z Reducing Health Disparities—improving the health of populations disproportionately affected by HIV, viral 
hepatitis, STDs, TB, and other related diseases and conditions.
z Encouraging Program Collaboration and Service Integration—striving to provide prevention services that 
are evidence-based, comprehensive, and high quality to appropriate populations at every interaction with the 
health care system.
z Maximizing Global Synergies—cultivating partnerships in prevention and research to maximize health impact 
around the world. 
This Center is one of the largest at CDC with approximately 1,500 employees dedicated to the prevention of these 
infectious diseases. 
The diseases addressed by NCHHSTP share a number of common indicators. They have similar or overlapping at-risk 
populations—including racial and ethnic minorities, men who have sex with men (MSM), and injection drug 
users. These diseases also have important interactions. Those who are infected with certain STDs, such as syphilis or 
gonorrhea, are at greater risk for HIV infection. Likewise, those who are infected with HIV are far more susceptible to 
TB disease because their immune systems are weakened. At risk individuals for these diseases also share similar social 
determinants, including poor access to health care, stigmatization, discrimination, and poverty. 
In the area of prevention and control, effective, science-based interventions exist to reduce the burden of TB, viral 
hepatitis, most STDs, and HIV. 
HIV/AIDS, viral hepatitis, STDs, and TB are among the most prevalent infectious diseases in the United States.  
Roughly 1.1 million Americans are living with HIV, the virus that causes AIDS. About 21% of those infected are 
unaware of their infection. 
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An estimated 18.9 million new cases of STDs (including HIV, human papillomavirus, herpes, chlamydia, gonorrhea 
and syphilis) occur each year in the United States. Chlamydia and gonorrhea are the two most commonly reported 
infectious diseases. These diseases are curable with antibiotics, but, because they are asymptomatic, people often do 
not know they are infected and do not seek treatment. Targeted STD screening programs are the most effective way to 
identify and treat them. 
In 2008, a total of 12,898 cases of TB cases were reported in the United States; the TB rate declined 3.8% from 2007 
to 4.2 cases per 100,000 people, the lowest rate recorded since national reporting began in 1953. Despite this overall 
improvement, progress has slowed in recent years. Foreign-born persons and racial/ethnic minorities continued to 
bear a disproportionate burden of TB disease in the United States. In 2008, the TB rate in foreign-born persons in the 
United States was 10 times higher than in U.S.-born persons. TB rates among Hispanics and blacks were nearly eight 
times higher than among non-Hispanic whites, and rates among Asians were nearly 23 times higher than among 
non-Hispanic whites. Among U.S.-born racial and ethnic groups, the greatest racial disparity in TB rates was for U.S.-
born blacks, whose rate was seven times higher than the rate for U.S.-born whites. Intensified efforts are needed to 
address the slowing decline in TB incidence and the persistent disparities that exist between U.S.-born and foreign-
born persons and between whites and minorities in the United States.
Hepatitis C virus is the most common blood borne infection in the United States, with an estimated 3.2 million people 
living with chronic hepatitis C. About half are unaware of their infection. There are also about 800,000 to 1.4 million 
people in the United States living with hepatitis B. Nearly 85,000 new infections of hepatitis A, B, and C have been 
reported annually in the United States. 
NCHHSTP People in Action 
Domestic HIV/AIDS Prevention
Since the beginning of the HIV/AIDS epidemic, CDC has worked to prevent HIV infections and reduce HIV-related 
illness and death. CDC currently funds programs that 1) help people learn their HIV status; 2) help high-risk HIV-
negative persons avoid infection; 3) support prevention services for persons living with HIV infection and link them to 
appropriate care and treatment services; and 4) help track the course of the epidemic and identify new interventions.
CDC addresses HIV/AIDS prevention through an array of public health activities including monitoring the disease’s 
impact, facilitating and supporting partnerships, implementing prevention programs, conducting intervention 
research and program evaluation, delivering technical assistance to build the capacity of organizations to offer 
prevention services, and developing policy and communications to support HIV prevention. These activities are 
conducted with public- and private-sector partners, including state and local health departments, community-based 
organizations and other nongovernmental organizations, universities, businesses, and the media. 
Although African Americans make up less than 13% of the U.S. population, they account for approximately 50% of 
persons estimated to be living with AIDS in the United States. To encourage focused, collaborative action among 
public health partners and community leaders, CDC launched the “Heightened National Response to the Ongoing 
HIV/AIDS Crisis among African Americans” (HNR) in March 2007. CDC invited 89 leaders representing the media, 
AIDS service organizations, faith and health communities, civil/social organizations, and the arts and entertainment 
industry. The leaders made commitments in three activities: awareness, communications, and testing. In May 2008, 
CDC held a 1-year HNR aniversary event where leaders shared their accomplishments from the past year and made 
new commitments for 2009. 
STD Prevention
CDC provides national leadership toward STD prevention through research, surveillance, policy development,  
and assistance to states, territories, and local health departments. CDC provides federal support for a community-
wide, science-based, interdisciplinary systems approach to STD prevention and conducts research to improve 
Infectious Diseases  |  Snapshot 2008
18
prevention services and to develop and refine interventions. Focus areas include preventing STD-related infertility in 
women, eliminating syphilis, preventing cancers related to sexually transmitted infections (STIs), preventing  
STI-related HIV transmission, reducing STI-related health disparities, and addressing the effects of social and 
economic determinants of STDs.
TB Prevention 
CDC has set a goal toward TB elimination in the United States (defined as less than one case per one million 
population). To accomplish this goal, CDC provides leadership and assistance to domestic and international efforts to 
prevent, control, and eliminate TB. CDC’s national program provides grants to states and other entities for prevention, 
control, and lab services; conducts clinical research for improving tools for diagnosing and treating TB; conducts 
epidemiologic and operational research to improve TB programs in the United States and globally; and supports 
medical consultation and training to improve awareness and clinical management of TB disease. TB priorities include 
interrupting TB transmission, reducing TB in foreign-born persons living or traveling in the United States, reducing 
TB in U.S. racial/ethnic minority populations, reducing the global impact of drug resistant TB, and reducing HIV-
associated TB.
Viral Hepatitis Prevention
CDC works to prevent viral hepatitis infections and their acute and chronic liver disease consequences. CDC educates 
health care and public health professionals to improve identification of persons at risk for chronic hepatitis C infection 
and ensure appropriate counseling, diagnosis, management, and treatment. CDC also conducts research and policy 
development to control hepatitis A and B, supports surveillance to detect new infections, and helps to ensure 
appropriate counseling, testing, and medical management of infected persons.
Communication Science, Health Marketing, and eChannels 
In FY 2008, NCHHSTP took a number of steps to increase social marketing campaigns. The STD Program awarded 
grants to the Centers for Excellence in Health Communication and Marketing at the University of Connecticut to 
study how young people might use mobile cell phone technology in viral marketing campaigns aimed at increasing 
awareness of the need for HIV testing. 
These grants followed innovative marketing efforts in mobile media. NCHHSTP, in collaboration with the Kaiser  
Family Foundation and CDC’s National Center for Health Marketing’s eHealth Division, has been working to expand  
the use of mobile channels to deliver prevention messages to young people at risk. These efforts were taken a step 
further through an innovative partnership with the University of Georgia’s New Media Center. Students developed 
“personal public service announcements”—short video messages about the need for HIV testing—which were 
distributed nationally by Verizon on its V-Cast network and through CDC’s YouTube channel, CDC MySpace, and other 
social media channels. 
This year, NCHHSTP continued to advance its use of the Web and new media by launching “Health Protection 
Perspectives,” a blog in which CDC’s partners and other interested parties can exchange ideas for the prevention of HIV, 
Hepatitis, STD, and TB. CONNECTIONS, an email-based newsletter for partners, also advanced program collaboration 
by providing updates across the center’s programs. 
Infertility Prevention 
One of NCHHSTP’s key priorities for STD prevention is increasing chlamydia screening of young women outside of 
traditional public health settings. Annual chlamydia screening of sexually active women 25 years and younger is 
recommended by CDC and other professional organizations to detect and treat women before chlamydia progresses to 
pelvic inflammatory disease, which can lead to infertility. The National Infertility Prevention Program, a collaboration 
between CDC and the Office of Population Affairs, funds chlamydia and gonorrhea screening and treatment services 
for low-income, sexually active women attending family planning, STDs, and other women’s healthcare clinics. 
However, a significant proportion of individuals screened or seeking medical care for STDs access services through the 
private or non-profit sectors.
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CDC Closely Monitors  
Surveillance Data to Identify Trends that Require Action
Study Finds One in 
Four Teen Girls Has  
a Sexually 
Transmitted Infection 
A CDC study released in March 2008 
estimates that one in four young 
women in the United States between 
the ages of 14 and 19—or 3.2 million 
teenage girls—is infected with at least one of the most common sexually transmitted diseases (human papillomavirus 
(HPV), chlamydia, herpes simplex virus, and trichomoniasis). The two most common STDs overall were human 
papillomavirus, or HPV (affecting 18 percent of teens tested), and chlamydia (affecting 4 percent of tested teenage girls). 
The study is the first to examine the combined national prevalence of common STDs among adolescent women in the 
United States, and provides the clearest picture to date of the overall STD burden in adolescent women.
The data demonstrates the significant health risk STDs pose to millions of young women in this country every year. The 
health effects of STDs for women—from infertility to cervical cancer—are particularly severe. Therefore, STD screening, 
HPV vaccination, and other prevention strategies for sexually active women are high public health priorities to prevent 
the devastating effects of these diseases. The study of STDs among teenage girls highlights the significant burden of STDs 
among girls and women, and identifies prevention strategies for reducing the toll of STDs in the United States.
The findings also served as a wake up call to Americans concerned with adolescent and teen health. Editorials in papers 
across the nation called for more open discussion between parents and teens, a national campaign about the risks of STDs, 
adherence to screening recommendations, and recognition that STDs are a concern to everyone. 
CDC Responds to State and Local Health Departments’ 
Requests for Epidemiologic and 
Laboratory Expertise
CDC epidemiology and laboratory staff 
played a critical role identifying outbreak 
of Hepatitis C at Nevada endoscopy clinic
On January 2, 2008, the Nevada State Health Division contacted CDC 
concerning surveillance reports received by the Southern Nevada Health 
District regarding two people recently diagnosed with acute hepatitis C. 
A third person with acute hepatitis C was reported the following day. 
These reports raised concerns about an outbreak because this health 
department typically confirms four or fewer cases of acute hepatitis C 
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per year. Initial inquiries found that all three of these infected people had undergone endoscopy procedures at the same 
clinic within 35—90 days of becoming ill. Nevada officials and staff from CCID’s Divisions of Viral Hepatitis (DVH) and 
Health Care Quality Promotion (DHQP) conducted an immediate joint investigation that identified a total of six cases 
among people who had undergone the endoscopy procedures within the same time period. The CCID Division of Viral 
Hepatitis laboratory conducted the initial molecular analysis that confirmed the association of hepatitis C virus among 
these patients. The joint epidemiological and laboratory investigation revealed that hepatitis C virus transmission likely 
resulted from reuse of syringes on individual patients and use of single-use medication vials on multiple patients at the 
clinic. Health officials advised the clinic to stop unsafe injection practices immediately, and approximately 40,000 patients 
of the clinic were notified about their potential risk for exposure to hepatitis C and other bloodborne pathogens. Following 
this investigation, comprehensive measures involving viral hepatitis surveillance, health-care provider education, public 
awareness, professional oversight, licensing, and improvements in medical devices were implemented to help ensure 
appropriate infection control measures were followed. 
CDC Scientists Continually Strive to 
Improve Abilities to Track and 
Understand Well Known  
and Emerging Disease Threats
Accurately tracking the HIV epidemic is essential to the nation’s HIV 
prevention efforts. Yet monitoring trends in new HIV infections has posed 
a major challenge since the beginning of the epidemic, especially since 
many HIV infections are not diagnosed until years after they occur. When 
gathering data on infection rates, researchers could not be certain if they were detecting new infections. Breakthrough 
technology in the form of a new laboratory test that can distinguish recent infections from those acquired more than five 
months before testing, allows the clearest picture to date of new HIV infections in the U.S. CDC has applied this advanced 
technology serologic testing algorithm for recent HIV seroconversion (STARHS) - to develop the first national surveillance 
system of its kind based on direct measurement of new HIV infections. 
Previous CDC estimates suggested about 40,000 people were newly infected with HIV each year. But those estimates 
used limited data gathered through less precise methods. Through this new technology, researchers discovered that while 
the annual rate of infections has not increased since the 1990s, the revised and more accurate estimated rate of new 
infections per year is 56,300, a 40 percent increase over the previous estimate. The data also confirm that the gay and 
bisexual men of all races and black men and women are most severely affected. African Americans represent nearly 50 
percent of new cases.
These findings not only provide a clear indication that the U.S. epidemic in the United States is far from over, but also 
provides critical information for improving prevention efforts. Prevention works, but has not reached many who need it. 
CDC’s first estimates from the STARHS system, published in the Journal of the American Medical Association in August 2008, 
revealed that the HIV epidemic is—and has been—worse than previously thought. 
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CDC Works Around the World to Combat Disease
Global AIDS Program and PEPFAR
CDC’s Global AIDS Program (GAP) is an important partner in the President’s Emergency Plan for AIDS Relief (PEPFAR), a 
multifaceted approach to combating HIV/AIDS in more than 120 countries around the world. Through PEPFAR, GAP works 
alongside other partners to provide direct scientific and technical assistance. GAP develops cutting-edge science and 
translates it to public health service delivery, by strengthening host country capacity to build self-reliant national public 
health systems. In FY 2008, PEPFAR was extended another five years, 
with the signing of the Tom Lantos and Henry J. Hyde United States 
Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria 
Reauthorization Act. 
In 2008, GAP strengthened laboratory networks for early infant 
diagnosis, developed demonstration protocols and testing algorithms, 
helped implement quality assurance/quality control programs, and 
conducted training on early infant diagnosis for laboratory technicians 
and healthcare providers. 
The Global AIDS Program has developed training materials on pre- 
and post-test counseling to caregivers; worked to strengthen care, 
treatment, and other referral services for vulnerable HIV-exposed and 
infected infants; and improved data monitoring and feedback systems 
for early infant diagnosis. GAP also provided leadership and worked 
with other organizations to strengthen laboratory capacity and systems for an effective and sustainable response to HIV.
With CDC’s leadership, early infant diagnosis is now being implemented in thirteen countries in Africa and  
two countries in the Caribbean region. 
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National Center for Preparedness, Detection, and Control of 
Infectious Diseases (NCPDCID)
The mission of the NCPDCID is to reduce the burden of infectious diseases domestically and globally through public 
health leadership, partnership, science, and action.  The center focuses on improving preparedness and response 
capacity for new and complex infectious disease outbreaks; integrating and improving laboratory services and 
capacity; and ensuring safe and high quality healthcare.  NCPDCID works with the agency’s national and global 
partners to conduct, coordinate, and support infectious disease surveillance, research, and prevention and to share 
vital information about infectious diseases. The Center has targeted programs on:
z Specific populations, such as immigrants, refugees, travelers, patients, and healthcare providers;
z Specific places, including U.S. and international borders and sites where newly emerging diseases can threaten 
global health; and
z Specific settings, such as laboratories, hospitals, outpatient clinics, nursing homes, dialysis centers, and other 
healthcare settings.
One of this Center’s greatest strengths is its workforce which includes:  laboratorians, infection control practitioners, 
information technology experts, statisticians, health economists, veterinarians, and health communication experts.  
The Center has nurses, medical doctors, and epidemiologists at U.S. and international sites, and health officials 
keeping the nation’s 20 quarantine stations on alert every minute of every day.
NCPDCID People in Action
Putting the statements above into practice is the focus of this Center—from efforts to stop the spread of staph in 
hospitals and the community to preventing U.S. introduction and spread of infectious disease at U.S. ports and land 
border crossings.
Preventing the Spread of Disease at Home 
Drug-resistant staphylococcus infections are a growing problem in the U.S., and often the culprit is methicillin-
resistant Staphylococcus Aureus—or MRSA. If not treated properly and quickly, MRSA can cause severe infection of 
the bloodstream or bones and even 
pneumonia. Each year, about 94,000 
people develop MRSA bloodstream 
infections, and nearly 19,000 die as a 
result.  Most serious MRSA infections occur 
in hospitals and other health care settings, 
however, more recently, MRSA skin 
infections have been spread in other 
settings where people are in close contact 
with others—such as schools and athletic 
locker rooms.  CDC partners with 
communities to educate the public about 
ways to prevent the spread of MRSA, including frequent hand-washing, keeping cuts clean and covered, and 
discouraging sharing of towels and other personal items.  
Another important emerging healthcare associated infection (HAI) is a new strain of Clostridium difficile, or C.diff. 
This toxic strain of bacteria can cause diarrhea and severe colitis.  Ten years ago, this bacterial strain was rarely seen. 
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Today, it has been found in many areas of the United States, Canada, and Western Europe.  More hospitals are seeing 
an increase in the number of patients with C.diff infections, that are resistant to many of the antibiotics normally used 
against the bacteria.
NCPDCID has worked with public and private partners to develop materials to educate hospital staff about protecting 
their patients from C. diff.  Strategies include adherence to infection control measures such as frequent hand washing, 
contact precautions, and environmental cleaning and disinfection.
Preventing the spread of infectious diseases to healthcare workers is an important part of infection control in 
hospitals, nursing homes, dialysis centers, urgent care centers, and other settings where patients receive care.  
Healthcare workers should follow recommended practices to protect themselves and their patients.
Safeguarding the Nation’s Donor Blood, Tissue, and Organs
In the U.S., almost 100,000 patients are on the transplant waiting list but only 25,000 organs are available for 
transplant each year. Tissue transplants have also increased, with over one million implants of musculoskeletal tissue 
alone being performed each year.  There is an urgent need to ensure the safety of donated organs.  All potential risks 
must be considered to make sure that transplant recipients have the best possible chance for good health.
To improve the safety of organ transplants and blood transfusions, NCPDCID works with private and public groups to 
ensure that problems are reported and acted on rapidly.  Not only have new screening processes been implemented, 
but numerous reporting mechanisms have been developed by CDC to share information on any adverse reactions 
quickly to reduce further negative consequences.
Monitoring the Safety of Immunizations
CDC works closely with partners to ensure that the United States continues to have the safest, most effective vaccine 
supply.  Serious vaccine side effects are rare and difficult to detect even with the well-designed large clinical trials that 
are conducted on vaccines before they are licensed.  Therefore, monitoring adverse events after vaccines are licensed 
for use is essential.  The rigorous monitoring is important for several reasons:
z To detect rare reactions;
z To protect people in higher risk groups;
z To maintain public confidence in vaccines.
The early warning system to detect problems possibly related to vaccines, Vaccine Adverse Event Reporting System 
(VAERS), is administered by NCPDCID in collaboration with the US Food and Drug Administration.  Anyone can report a 
suspected problem to VAERS by phone, online, or by mail. 
Preventing the Spread of Disease at U.S. Ports and Land Border Crossings
CDC has legal authority to prevent U.S. importation and spread of communicable diseases.  Federal isolation and 
quarantine are authorized for communicable diseases including cholera, diphtheria, infectious tuberculosis, plague, 
smallpox, yellow fever, viral hemorrhagic fevers, SARS, and flu that can cause a pandemic.
CDC has 20 quarantine stations at U.S. port cities and land border crossings where most international travelers arrive.  
These stations are operated by NCPDCID staff and play a critical role in protecting public health.  CDC also trains 
Customs and Border Protection officers and others in airports and seaports to recognize signs that a traveler may have 
an infectious disease which could spread from person to person.
Promoting Health of Refugees
Through its Refugee Health Program, NCPDCID is working to expand the required overseas medical exam to include 
screening refugees for health problems before U.S. arrival.  In each country, the screenings and treatments are tailored 
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to meet the refugees’ unique needs.  A recent CDC analysis estimates that immunizing more than 50,000 refugees 
overseas would save about $13 million in health care costs.  Improving the health of refugees contributes to their 
successful resettlement and decreases the risk of U.S. importation and spread of disease.
The Emerging Infections Program (EIP)
Across the country, ten state health departments and a host of partners work closely with CDC to conduct surveillance 
and determine the best ways to prevent the spread of emerging infectious diseases.
Each EIP is coordinated by a state health department and an academic medical center in the state.  In Tennessee, for 
example, the health department teams up with Vanderbilt University.  In Connecticut, the health department 
partners with Yale University and the University of Connecticut.  Professors and researchers collaborate to collect data 
on new infectious diseases, evaluate activities to prevent their spread, and to provide vital information to develop 
new policies to protect the public from emerging infectious diseases.
Preparing for a Flu Pandemic 
Since 2004, more than 350 cases of humans infected with avian influenza A (H5N1) have been reported around the 
world, mainly in Asia. Many of those infected have died.  Because this flu has the ability to evolve into a strain that can 
spread easily between people, CDC and its partners around the world closely monitor any cases of person-to-person 
transmission of H5N1.  
Until recently, diagnosing this flu was difficult, time-consuming, and costly.  A new rapid diagnostic test developed 
by CDC changed that.  This test has been distributed to Laboratory Response Network (LRN) labs across the country.  
Now laboratories in the public health, veterinary, military and federal sectors have this highly reliable, low-cost test 
to detect H5N1 virus.  As a result, the United States is better prepared to detect an influenza outbreak caused by this 




Laboratory Response Network (LRN) 
In 1999, the Laboratory Response Network (LRN) was established by the CDC in conjunction with the Federal Bureau 
of Investigation, and the Association of Public Health Laboratories. The LRN’s mission is to maintain an integrated 
national and international network of laboratories that are fully equipped to respond to acts of chemical or biological 
terrorism, emerging infectious diseases, and other public health threats and emergencies. 
The LRN now includes approximately 160 federal, state, and local public health, veterinary, military and international 
labs. These labs provide public health, food, veterinary, and environmental testing capabilities. LRN laboratories 
conduct the necessary tests to rapidly detect threat agents and other organisms that could lead to disease outbreaks. 
More than ninety percent of these labs can perform tests to detect causative agents of Anthrax, Tularemia, and plague 
and many can test for the causative agents of other threats such as meliodosis, ricin toxins, staphylococcal enterotoxin 
B, non-variola orthopoxvirus, and influenza A/H5 (Avian lineage) virus. Since its inception, the LRN has significantly 
improved lab capacity at the state, local, federal and international levels. CDC has trained more than 9,000 clinical 
laboratorians in the detection, diagnostics, and reporting of public health emergencies. 
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CDC Scientists Work with Healthcare Professionals  
to Reduce Infections and Save Lives
Bloodstream infections associated with a central line, a type of venous catheter, are among the most common type of 
healthcare-associated infections (HAIs), with an estimated 250,000 cases occurring in United States hospitals each 
year.  The estimated attributable mortality is 12%-25% for each infection.  The marginal cost to the health-care system is 
approximately $25,000 per episode.  In recent years, there have been successes in preventing these infections when 
following CDC’s guidelines and recommendations.  For example:
z In hospitals participating in CDC’s National Healthcare 
Safety Network (NHSN), the rate of central line-
associated bloodstream infections among patients in 
intensive care units decreased by 40%-50% during the 
last decade. In most major intensive care unit types, 
rates also decreased 50% for the subset of central 
line-associated bloodstream infections associated with 
methicillin-resistant Staphylococcus aureus (MRSA).  
z Several states using NHSN for mandating reporting 
of healthcare-associated infections have identified 
prevention of bloodstream infections as a priority.  For 
example, by adopting multiple recommended practices, 
infection rates in New York have declined more than 
70% in intensive care units participating in the Greater 
New York Hospital Association Prevention Collaborative.  
Following CDC recommendations and using standard 
methods of measuring success through NHSN has had a  
substantial impact on efforts to prevent central line-associated bloodstream infections.  CDC plans to build on the 
successes in reducing bloodstream infections by developing and implementing similar strategies for reducting of  
other healthcare-associated infections.
Trends in central Line-Associated Bloodstream Infections (CLABS) 
by Intensive Care Unit Type—United States 1997–2007*
*2005 CLABSI rates estimated from loglinear models  
of annual CLABSI trends; no 2005 data available from  
National Healthcare Safety Network (NHSN)
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CDC Focuses on At-Risk Populations to Prevent  
Spread of Infectious Diseases
CDC is working on many programs to 
decrease morbidity and mortality  
among immigrants and refugees and  
to prevent disease from entering the  
United States. 
These efforts include implementing revised 2007 tuberculosis technical instructions (TB TI).
By the end of fiscal year 2008, 28% of U.S.-bound immigrants were being screened for tuberculosis under the 2007 TB 
TI.  Implementation of these new TB TI may result in three times as many cases of tuberculosis being detected overseas 
and treated prior to arrival in the U.S. Diagnosis and treatment overseas decreases the burden of illness among persons 
entering the U.S. and results in estimated annual cost savings to states of over $2 million.  Additional information about 
the 2007 TB TI can be found at www.cdc.gov/ncidod/dq/panel_2007.htm. This is one of the many ways CDC is providing 
leadership in the global effort to control tuberculosis. 
CDC’s Arctic Investigations Program (AIP) located in  
Anchorage, Alaska since 1973.
AIP’s mission is to prevent infectious diseases in Arctic and sub-Arctic populations, with an emphasis on indigenous 
people’s health.  The AIP works closely with Alaska Native Tribal Health organizations to improve infectious disease 
prevention activities by providing health data, laboratory expertise, focused investigations, and interventions.  Recent 
activities include detecting an outbreak of invasive pneumococcal infections among Alaska Native children due to 
bacterial strains not covered by current vaccines. 
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CDC is a Leader in Specialized Training Programs
In an effort to help address a national shortage of veterinarians certified to work with laboratory animals, the Centers for 
Disease Control and Prevention (CDC) has begun a new residency program in laboratory animal medicine. One of about 
40 such programs in the country, the CDC program combines classroom training with hands-on experience in CDC’s most 
sophisticated high-containment laboratories to help  prepare veterinarians for careers in biomedical research.
The two-year training program, which is a partnership between CDC and nearby Emory University’s Robert W. Woodruff 
Health Sciences Center, began in July 2008 with its first two residents.
National Center for Zoonotic, Vector-Borne,  
and Enteric Diseases (NCZVED) 
The mission of NCZVED is to execute a multidisciplinary strategy to prevent, control, and, where possible, eliminate 
infectious diseases within a larger ecological context that includes humans, animals, and plants interacting in 
a complex, ever-changing natural environment. This center provides national and international scientific and 
programmatic leadership to address zoonotic (transmitted from animals to humans), vector-borne (from organisms 
such as mosquitoes, or ticks), food-borne, waterborne, mycotic (fungal), enteric (intestinal) and related infections to 
identify, investigate, diagnose, treat and prevent these diseases. 
Multiple factors have come together to create a new epidemiologic era characterized by increases in emerging and 
reemerging infectious diseases. Recent threats such as SARS, avian influenza, and West Nile virus as well as continued 
resurgence of diseases such as dengue and malaria demonstrate that animals, people, and the environment are 
inextricably linked, that animal health strategies impact public health, and that the strategies to protect both must be 
coordinated.
Gaining a better understanding of these diseases and the ecologies from which they have emerged requires extensive 
interaction and collaboration across CDC and the traditional public health community, as well as the agricultural, 
wildlife, companion animal, and environmental agencies and organizations. 
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NCZVED People in Action
Infectious Diseases Pathology 
NCZVED’s Infectious Disease Pathology Branch (IDPB) serves as the nexus of CDC’s unique capacity to rapidly 
diagnose and respond to individual cases or clusters of unexplained severe illness or death. In the past year, IDPB 
has collaborated on investigations of unexplained severe illness and death at a correctional facility in Texas, cases of 
yellow fever vaccine-associated deaths in Peru, myocarditis in New England, and an occupationally acquired fatal case 
of plague in Arizona. This cross-cutting program that functions, as needed, to support multiple divisions across CDC.
Development of Dengue Vaccine 
Dengue is a mosquito-borne disease affecting upwards of 50 million people annually. A dengue vaccine has the 
potential to greatly reduce incidence of the disease, possibly eliminating the virus from endemic regions. The pre-
clinical development of a novel dengue vaccine has been completed, and commercial partnerships have been formed 
with manufacturers in the United States and India. The vaccine will begin phase one clinical trials in summer 2009.
Launch of National Outbreak Reporting System (NORS) and Prevention of Waterborne Diseases 
The recent launch of NORS brought together, for the first time in a single system, the electronic reporting to CDC 
of food, water, person-to-person, and animal-to-person outbreaks. As part of NORS, the Waterborne Disease and 
Outbreak Surveillance System, created by CDC, the Environmental Protection Agency (EPA), and the Council of State 
and Territorial Epidemiologists (CSTE) in 1971, will now be fully electronic. It is expected that the transition from a 
paper-based to electronic surveillance system will improve the speed, accuracy, and completeness of waterborne 
disease outbreak reporting. 
Climate Change 
Climate and weather are major drivers of the distribution and incidence of vector-borne diseases. To address the 
influence of climate on vector-borne diseases, NCZVED created a team of ecologists, mathematical modelers, 
vertebrate ecologists, and entomologists. The team has already modeled effects of weather and climate on 
dengue virus transmission in Puerto Rico and created prediction models for West Nile virus in Colorado and for 
plague in the Southeastern United States and Uganda. NCZVED created operational plans with CDC’s National 
Center of Environmental Health (NCEH) to expand climate-related activities at CDC and drafted a memorandum of 
understanding for future collaboration with the National Center for Atmospheric Research. 
Arboviral Disease and Blood Safety
NCZVED worked with the Food and Drug Administration (FDA) and industry to implement and evaluate the impact 
of universal blood donor screening for West Nile virus (WNV). This system has detected and prevented transfusion of 
WNV from more than 1200 infected blood donors. The integrity and effectiveness of this system has been evaluated 
through investigation of possible transfusion transmitted WNV cases as well as by mathematical modeling of empiric 
screening data. The latter has resulted in major changes in screening strategy that have increased the effectiveness of 
the system in the most cost-efficient manner. In addition, the presence of dengue virus has been discovered in the US 
blood supply and strategies for other emergent arboviral threats to blood safety, such as chikungunya virus, are being 
examined.
Unexplained Neurologic Illness among Pork Processing Plant Workers 
In 2007-2008, CDC assisted state health departments in the investigation of an unexplained neurologic illness 
among workers at pork processing plants in several states. The original cluster was identified by the Minnesota 
Department of Health among workers at a single processing plant who suffered from an illness that was later termed 
“progressive inflammatory neuropathy” (PIN). The investigation in Minnesota indicated that PIN was associated with 
having worked in close proximity to the “head table”, where a process using compressed air to extract pig brains 
potentially exposed workers to aerosolized brain material. A follow-up survey of 25 large pork processing facilities 
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determined that use of this technique is uncommon and only two other plants, one each in Indiana and Nebraska, 
similarly extracted brains using compressed air. As of May 2008, the number of persons identified with PIN include: 18 
confirmed cases in Minnesota; 6 confirmed cases in Indiana; and 1 confirmed case in Nebraska. Although the etiology 
of PIN remains unknown, there is no evidence that the illness is transmitted person-to-person, or that there is any risk 
to consumers through food-borne transmission.
Idaho Splash Parks Outbreak 
In 2007, two outbreaks associated with splash parks were identified in Idaho. Splash parks are recreational water 
venues consisting of multiple interactive fountains or spray devices that do not have above-ground standing 
water. The first was a cryptosporidiosis outbreak, involving 51 cases. The second was an outbreak of E. coli O157:H7 
infections, involving in 31 cases. Human behaviors, such as swimming while ill with diarrhea, and ingesting the water, 
are thought to be contributing factors to the outbreaks. As part of the response, Idaho local public health districts 
were considering proposing legislation in August 2008, to increase oversight of splash parks. At the request of the 
Idaho State Epidemiologist, CDC assisted in an investigation to determine the frequency of non-hygienic behaviors 
occurring at splash parks. These data were needed to direct the development of the legislation. An observational 
study conducted at four splash parks found that children exposed their buttocks to splash features a mean of 29.4 
minutes per 60 minutes of observation and placed their open mouths to splash features a mean of 9.9 minutes per 
60 minutes of observation. A survey of adult supervisors of children at the splash parks conducted concurrently found 
that adult supervisors frequently reported never bathing their children with soap and water prior to the children’s 
entering the water and never telling their children not to sit on top of the splash features. Educational materials have 
been developed to address these issues in an effort to reduce the spread of these types of diseases. 
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CDC Responds to Requests 
From Foreign Ministries  
of Health
In July 2008, a Dutch tourist died of Marburg viral 
hemorrhagic fever following her return to the 
Netherlands from a vacation in Uganda. The tourist had likely acquired the infection through exposure to bats while 
visiting a Ugandan cave. The Uganda Ministry of Health requested assistance from CDC to help respond to the potential 
public health emergency.  In early August, CDC sent a team to create and distribute important health messages about safe 
travel to Uganda.  To further investigate the ecology of Marburg virus in bats in Uganda, CDC sent a second team to collect 
and test the specimens for analysis at CDC headquarters in Atlanta. This analysis is expected to result in more information 
about the virus’ characteristics and lead to further public health recommendations.  
The success of this collaboration between CDC and the Ugandan Ministry of Health is attributable to CDC’s technical 
expertise and the willingness of Ugandan authorities, both public and private, to work together.  The materials will be 
distributed broadly and authorities also plan to develop surveys to gather additional data from international travelers to 
Uganda, the Uganda Wildlife Authority staff, and the tourism industry about how to promote safe, healthy travel. 
CDC Laboratory Scientists  
Constantly Improving Detection Methods
New genetic sequencing techniques developed at CDC have allowed complete genome generation of emerging Old World 
lyssaviruses—viruses associated with rabies. Application of a direct rapid immunohistochemical test has led to enhanced 
rabies surveillance in parts of Africa and Asia. And, recent development of an innovative canine vaccine offers a unique 
opportunity for rabies control in canine and human populations. 
Poxvirus is the family of viruses that includes smallpox, monkeypox, and cowpox among others. Some of these viruses 
(excluding smallpox) are still affecting animal and human populations in various parts of the world. Over the past year 
CDC’s Poxvirus program has used the recently developed 454 Life Sciences sequencing technology to address questions 
relevant to poxvirus, transmission, and evolution. This technology has contributed to an improved understanding of the 
genetic diversity of monkeypox throughout its native range in sub-Saharan Africa. This will increase our understanding of 
transmission of this increasingly common zoonotic disease and will help identify high risk geographic areas that may be 
serving as sources of human infection. This 
technology proved invaluable as the only method to 
successfully identify and provide genetic 
characterization of a novel, human pathogenic 
poxvirus isolated from upstate New York.
CDC has collaborated to produce a Botulinum Toxin 
ELISA Kit for use by the Laboratory Response Network 
(LRN) and Food Emergency Response Network (FERN) 
eliminating the need for animal studies. The ELISA kit can rapidly screen foods involved in botulism.  The use of this new 
product demonstrates the enhanced US capacity to respond to bioterrorism events involving botulinum toxin.  In addition, 
CDC has developed a test that can be used in diagnosis and surveillance of multiple types of Salmonella.
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CDC Helps Solve Food-Borne Outbreak Mystery 
The recent Salmonella Typhimurium outbreak 
associated with peanut butter-containing products 
led to more than 700 reported cases and may have 
contributed to nine deaths.  The broad distribution of 
peanut butter and peanut paste shipped from a single 
plant to food manufacturing companies throughout 
the country triggered the recall of more than two 
thousand food products.
This outbreak demonstrates the challenge of 
"ingredient driven" outbreaks.  The implicated 
product was first identified by the Minnesota Department of Health, which identified peanut butter distributed to 
institutions as a likely source and then isolated the outbreak strain of Salmonella Typhimurium from an open container of 
peanut butter. However, peanut butter from institutions did not account for all the illnesses.  Ongoing patient interviews 
indicated that many patients did not eat peanut butter in institutions, but had eaten various other peanut butter-
containing products.  During January, a second case-control study was conducted by CDC and state and local health 
departments to further assess exposures.  Preliminary analysis found that patients were more likely than controls to have 
eaten prepackaged peanut butter crackers. The associated “ingredient driven” aspect was uncovered with the recognition 
that contaminated peanut paste (and some of the peanut butter) from the processing plant was used as an ingredient in 
numerous peanut butter containing products, including cookies, crackers, ice cream, frozen  
meals, and dog treats. 
This outbreak is an example of how contamination in one place can lead to illnesses across the country. These types of 
outbreaks present two major challenges: 
1. It is difficult to identify the source of the outbreak when the contaminant is in a wide range of foods, and 
2. It is difficult to trace and recall the many foods affected and to provide immediate guidance to the public. 
This outbreak also underscores the need to detect and respond to outbreaks more quickly, including deceasing the time 
taken for DNA fingerprinting of Salmonella in state labs, rapid interviews of cases by state/local public health departments 
to provide vital clues about the source, and more quickly coordinating nationwide studies to confirm the source.
CDC will continue to focus on research, education, and training to assist local, state, and national efforts in preventing 
food-borne illnesses, enlist food industries into prevention, response, and information sharing; and bolster state health 
capacity to effectively and promptly identify and respond to outbreaks. 
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For Vectorborne Infectious Diseases, Surveillance Must 
Include the Animal Hosts as well as Human Disease
Vectorborne zoonoses like West Nile virus (WNV), plague, and Rocky Mountain spotted fever (RMSF) exemplify the 
complex ecologies that impact public health. Surveillance programs intended to predict the risk of these diseases must 
monitor zoonotic as well as human epidemiology. ArboNET is an example of such an integrated surveillance system. 
It captures human case data, blood donor data, as well as environmental surveillance indicators (virus identified in 
mosquitoes, dead birds, horses, sentinel chickens) for WNV and other domestic arboviruses (such as St. Louis encephalitis 
and eastern equine encephalitis). It can also capture information about imported zoonoses, such as chikungunya and 
Japanese encephalitis. 
Timing of WNV-Positive Mosquito Pool  
Collection and Human WNV Case Onset,  
By County, United States, 2006
Legend:
Counties reporting human cases before mosquito collection yielding WNV-positive mosquitoes
Counties reporting mosquito collection yielding WNV-positive mosquitoes before human cases reported
In 2006, WNV-positive mosquitoes were collected in 180 counties before reports of human cases, raising the possibility 
that enhanced control measures and encouragement for people to use personal protection could have prevented illnesses. 
Over 50% of counties that have positive mosquito pools report at least one human case, so the finding of WNV-positive 
mosquitoes may serve as an early warning indicator.





The success of the CDC’s efforts to combat infectious diseases depends upon sharing innovations, science, research, 
vaccines, surveillance and information between a vast array of partners, nationally and around the globe.  The 
knowledge shared goes both ways—into and out of the CDC.  Partners are individuals, schools, colleges and 
universities, private laboratories and pharmaceutical companies, local, state, and federal labs and health 
departments, foreign governments, organizations involved in the myriad of activities focused on public health as well 
as each member of the general public. CCID allocates 87 percent of its annual budget to supporting external partners 
and programs.
Supporting States and Territories
Much of the CDC Infectious Disease annual budget is used to assist state and local public health departments.  CDC 
regards the cooperation and collaboration between the agency and its state and local partners as crucial to the success 
of public health measures.  Every state and each U.S. territory receives funding from CDC to support their local public 
health programs. In addition, CDC directly funds initiatives in thirteen major metropolitan areas: Baltimore, Chicago, 
Cincinnati, Detroit, Houston, Los Angeles, Monroe County, NY, New York City, Oakland-Alameda County, Philadelphia, 
San Antonio, San Diego, and San Francisco. 
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CCID also funds numerous international public health programs and collaborates with foreign public health 
departments and universities while striving to improve public health throughout the world. A list of these 
organizations appears in the Appendix.
Funding a variety of programs through grants and cooperative agreements allows CCID to assist with a myriad of 
cutting edge research, outreach and development programs that work collectively to expand that nation’s and the 
world’s health. 
CDC is especially proud of the work it does funding and fostering relationships between CCID, its national centers and 
various institutions of higher learning throughout the country. In 2008, CCID gave nearly $370 million to 56 academic 
organizations in the U.S. 
Reference Labs
CDC laboratories are uniquely positioned to provide reference diagnostic services to other public health laboratories. 
CDC laboratories have the capability of identifying virtually all the bacteria, viruses, fungi, and parasites that infect 
humans, a claim that that is unique to CDC. Additionally, CDC scientists have the tools to characterize subspecies and 
subtypes of organisms using assays that are not readily available commercially. Thus, public health laboratories send 
specimens to CDC for identification or characterization when they either cannot perform these tests or confirm their 
results of unusual organisms. CDC has a unique relationship with public health department laboratories in all the 
states. The state public health departments are required to monitor the presence of important infectious diseases 
(nationally notifiable diseases—NND) and to serve as the reference point of contact for clinical laboratories in their 




WHO Collaborating Centers 
The World Health Organization, WHO, is a specialized agency of the United Nations with 191 member states including 
the U.S. WHO promotes technical cooperation for health among nations, carries out programs to control and eradicate 
disease, and strives to improve the quality of human life.
WHO has four main functions:
1. to give worldwide guidance in the field of health;
2. to set global standards for health;
3. to cooperate with governments in strengthening national health programs; and
4. to develop and transfer appropriate health technology, information and standards.
WHO works in partnership with other organizations in the United Nations system, including UNICEF, UNDP, 
UNFPA, UNESCO, World Bank, ILO, UNEP, FAO and cosponsors UNAIDS. WHO also works with bilateral agencies, 
intergovernmental and nongovernmental organizations (NGOs), and has designated nearly 1,200 leading health-
related institutions around the world as WHO Collaborating Centres. These collaborating centers work with WHO 
on areas such as nursing, occupational health, communicable diseases, nutrition, mental health, chronic diseases 
and health technologies. In line with the WHO policy and strategy of technical cooperation, a WHO collaborating 
centre must also participate in the strengthening of country resources, in terms of information, services, research 
and training, in support of national health development. Of the 35 CDC/WHO Coordinating Centers located on CDC 
premises, most of them are engaged in activities relating to infectious diseases. 
The WHO/CDC Collaborating Centers are: 
z Dengue and Dengue Hemorrhagic Fever Reference and 
Research
z Control and Elimination of Lymphatic Filariasis in the 
Americas
z Prevention and Control of Malaria
z Production and Distribution of Malaria Sporozoite 
ELISAs
z Surveillance of Human African Trypanosomiasis, 
Treatment Failure and Drug Resistance
z Quality Control for Pesticides and Evaluation of 
Insecticides
z Research, Training and Eradication of Dracunculiasis
z Complex Emergency Preparedness and Response
z Environmental Epidemiology
z Reference and Research on Rabies
z Physical Activity and Health Promotion
z Reference and Research in Blood Lipids
z Prevention and Control of Epidemic Meningitis
z Research and Reagents for Human Immunoglobulin 
Subclasses
z Applied Biosafety Programs and Training
z Reference and Research on Viral Hepatitis
z Viral Hemorrhagic Fevers
z Reference and Research on Rickettsial and Bartonella 
Associated Diseases
z Injury Control
z Acquired Immunodeficiency Diseases
z Reference and Research in Syphilis Serology
z Shigella
z Rotavirus and the Agents of Viral Gastroenteritis
z Arthropod-Borne Viruses
z WHO Family of International Classifications for North 
America
z Global Public Health Workforce Development
z Surveillance, Epidemiology and Control of Salmonella 
and other Food-borne Diseases
z Surveillance, Epidemiology and Control of Influenza
z Smallpox and Other Poxvirus Infections
z Global Tobacco Surveillance
z Reference and Research on Plague Control
z Reproductive Health
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CCID At Work Abroad—Global Health
CCID At Work Abroad— 
Global Health 
Since 1946, beginning with CDC’s work in malaria control, and subsequent focus on cholera and smallpox outbreaks, 
the scope and nature of CDC’s global engagements have been dramatically enhanced. CCID’s global health mandate 
has expanded to include other diseases and conditions, and has been broadened to include the goal of protecting 
the US and world population from emerging global threats. CCID provides leadership expertise and collaborates 
with partners around the world to increase life quality and expectancy, especially among those at highest risk 
for premature death— particularly vulnerable children and women. CDC is also committed to increasing global 
preparedness to prevent and control naturally occurring and man-made threats to health. 
Evidence of this commitment is demonstrated by the fact that CDC has 224 staff assigned to 54 countries, 40 staff 
detailed to international organizations, 1,200 locally employed staff and 6,000 temporary duty assignments for 
technical assistance. CDC’s areas of particular expertise that are shared with our global partners include: surveillance, 
disease detection, epidemiology, laboratory support, training, intervention, care and operations research. 
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International Emerging Infections Program (IEIP)
The International Emerging Infections Program is a very important and critical program to Global Health activities 
across the CDC.  IEIP, modeled in part on the U.S. Emerging Infections Program, is comprised of six centers of 
excellence around the world.
This program aims to lessen the burden of infectious diseases by providing expert technical assistance: detecting and 
investigating outbreaks to control them sooner; monitoring disease emergence and trends so that policymakers can 
make more informed and effective decisions about prevention measures; and, strengthening global public health 
infrastructure. The first IEIP was established in Thailand in 2001, and as of 2008, IEIPs are also located in Bangladesh, 
China, Egypt, Guatemala, and Kenya.
Global Immunization Division
CDC supports global immunization initiatives to protect American children from vaccine-preventable diseases (VPDs) 
imported into the United States or acquired abroad, for humanitarian reasons, and to protect against the medical 
costs of morbidity and mortality associated with VPDs. CDC is one of the spearheading partners for global polio 
eradication, measles mortality reduction, and Global Immunization Vision and Strategy initiatives along with a 
substantial network of partner agencies. 
Pneumonia and meningitis are major killers of young children in the developing world. For a variety of economic and 
other reasons, vaccines to prevent these diseases are often underutilized or unavailable. In response, CDC is working 
with partners around the world to make life-saving vaccines available to those who need them most.
 While a vaccine targeting Haemophilus influenzae type b (Hib) disease has been available for years, uptake in 
developing countries has been slow until recently. CDC epidemiologists and laboratory scientists are supporting 
efforts in a number of these countries to establish the burden of Hib and pneumococcal diseases, documenting the 
impact of vaccination, and evaluating vaccination strategies. 
In the “meningitis belt” of sub-Saharan Africa—extending from Ethiopia in the east to Senegal in the west—
bacterial meningitis is caused by Neisseria meningitidis serogroup A, a strain that rarely causes disease in 
industrialized countries, and for which there is not yet a vaccine to effectively protect young children. As part of its 
work with global partners to encourage the adoption of new vaccines, CDC has been collaborating with the Meningitis 
Vaccine Project (MVP) to create and test a Neisseria meningitidis serogroup A vaccine for Africa and other low-income regions.
CDC has collaborated with WHO and other international health partners to develop training curricula to guide the 
development and implementation of national pandemic plans. In addition, CDC is helping countries threatened by 
avian influenza to develop rapid response teams, enhance their flu surveillance systems, and implement advanced 
laboratory diagnostic techniques. 
Global AIDS Program
HIV/AIDS continues to be one of the most severe health challenges today. In 2000, CDC created the Global AIDS 
Program (GAP). Currently, the program supports national HIV/AIDS programs in more than 80 countries in Africa, 
Asia, Central and South America, and the Caribbean through its country and regional offices. GAP assists resource-
constrained countries to prevent HIV infection, improve treatment, care and support for people living with HIV. The 
program also continues to build vital capacity and infrastructure to address the global HIV/AIDS epidemic.
The Global AIDS Program (GAP) is a partner in the President’s Emergency Plan for AIDS Relief (PEPFAR), a multifaceted 
approach to combating the HIV/AIDS epidemic in over 120 countries around the world. GAP works with partners to 
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provide direct scientific and technical assistance and translates this science into public health service delivery. GAP 
also works with other countries’ Ministries of Health to build their public health systems.
CDC’s contributions to PEPFAR, in partnership with ministries of health and its U.S. Government colleagues, have 
helped to achieve the following results: 
z 2.1 million men, women and children have received antiretroviral therapy. 
z 16 million pregnant women have participated in preventing mother-to-child  
transmission of HIV. 
z 240,000 infant infections have been prevented.
During the first five years of PEPFAR, CDC: 
z Provided leadership on over 125 studies, ensuring scientifically sound interventions; 
z Helped build sustainable laboratory infrastructure to respond to HIV and other diseases; 
z Helped implement innovative surveillance systems and data for epidemiologically driven decision-making; 
z Spearheaded HIV Prevention in Care and Treatment Settings for HIV-infected individuals; 
z Partnered with HRSA to support massive scale-up of antiretroviral treatment to adults and children and increase 
pregnant women’s participation in programs to prevent mother-to-child transmission; and 
z Researched and developed the Basic Care Package, a package of interventions that is  designed to minimize the 
susceptibility of HIV-positive persons to common opportunistic infections and illnesses spread by unsanitary water. 
International Tuberculosis Control Technical Assistance 
Because TB kills 1.6 million a year worldwide and because most cases of TB in the United States are among foreign-
born persons, it is critical for the United States to assist in international TB control. CDC’s NCHHSTP provides leadership 
and technical assistance in controlling TB internationally for PEPFAR and GAP-related activities. In FY 2008, CDC staff 
provided technical assistance in 40 countries. CDC’s global technical assistance for TB includes: 
z Deploying outbreak response teams 
z Improving access to TB drugs 
z Developing TB testing standards 
z Building capacity of health care providers 
z Collaborating with other international partners to develop and implement the global plan to combat XDR TB 
z Providing technical assistance to expand program capacity 
z Supporting TB communication and education efforts. 
In addition to working closely with ministries of health in other countries, CDC works with other federal agencies 
and with multilateral organizations such as WHO and the International Union Against Tuberculosis and Lung Disease; 
foundations, including a Bill and Melinda Gates Foundation-funded collaboration and the Foundation for Innovative 
Diagnostics; and non-governmental organizations. CDC is a founding member of the WHO Stop TB Partnership, a 
global effort of more than 500 governmental and non-governmental organizations.
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Global Malaria Program
In 1946, CDC was established, descending from the wartime agency, Malaria Control in War Areas (MCWA). More than 
60 years later, CDC, through CCID, continues to support the prevention and control of malaria throughout the world 
in partnership with state and federal agencies, national and international organizations, and foreign governments. 
Having conducted key research that has informed the current generation of malaria control interventions, CDC’s 
strategic and applied research efforts seek to refine these interventions as well as develop new ones to stay ahead of 
the curve—and to contribute to achieving ambitious global goals of malaria elimination and ultimately eradication.  
CDC also conducts domestic activities, among them, providing U.S. malaria surveillance and consulting with clinicians 
on management of cases. 
President’s Malaria Initiative 
The President’s Malaria Initiative (PMI) is led by the U.S. Agency for International Development (USAID) and together 
USAID and CDC jointly implement the initiative, a 5-year, $1.2 billion program to cut malaria deaths in half in 15 
African countries.  PMI focuses on implementing proven prevention and treatment measures on a national scale.  CDC 
lends particular expertise to PMI in monitoring program implementation and documenting outcomes and impact, 
as well as in entomological assessment.  By the end of 2008, PMI had provided more than 30 million people with 
lifesaving interventions. PMI has:
z Procured more than 2.3 million doses of intermittent preventive treatment for pregnant women;
z Procured more than 28 million treatment courses of highly effective  
artemisinin-based combination therapy (ACTs);
z Distributed approximately 9 million long-lasting insecticide-treated mosquito nets (LLINs);
z Supported spraying the inside of homes with insecticides in 14 countries,  
covering nearly 25 million in 2008 alone; and
z Trained more than 29,000 health workers in the correct use of ACTs.
More importantly, we are starting to see results: data from Malawi, Mozambique, mainland Tanzania, Rwanda, 
Zambia and Zanzibar show that major reductions in the malaria burden are possible, sometimes more quickly than 
anticipated.
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Infectious Diseases  
Budget Overview
The CDC total FY 2008 budget appropriated by Congress was roughly $10.6 billion (B). The Coordinating Center for 
Infectious Diseases (CCID) receives more than half of that amount—about $6.6B. A portion of these funds is directly 
appropriated by Congress to a budget line item aptly named Infectious Diseases. Also, CCID receives resources from 
other CDC directly appropriated budget lines including: Health Information and Service, Global Health, Public Health 
Improvement and Leadership (PHI & L), and Terrorism. 
In addition to directly appropriated funding, financial resources are also transferred to CCID from other government 
departments and agencies to support public health-related programs such as Vaccines for Children, President’s 
Emergency Plan for AIDS Relief (PEPFAR), and the Congressional Black Caucus. 
Transfers To CCID
Vaccines for Children Program—$2.8B Transfer from  
Centers for Medicare and Medicaid Services (CMS)
The Vaccines for Children Program (VFC) program is an entitlement program that provides vaccines for children 
though 18 years of age through enrolled private providers and public health clinics. VFC eligibility includes children 
who meet one of the following requirements: uninsured; Medicaid-eligible; American Indian/Alaska Native; or 
underinsured children who receive vaccines through Federally Qualified Health Centers or Rural Health Clinics. The VFC 
program accounts for more than 40% of the vaccines purchased in the United States for children and adolescents.
PEPFAR—$1.5B Transfer from the State Department
In 2003, President Bush launched the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to combat global 
HIV/AIDS. This was the largest commitment by any nation to combat a single disease in history. The goals of PEPFAR 
include support for treatment for 3 million HIV infected people, support for prevention of 12 million new infections, 
and support for care for 12 million people infected or affected by HIV/AIDS including 5 million orphans and vulnerable 
children. Through PEPFAR, the U.S. Government is working with international, national and local leaders worldwide 
to accomplish these goals. To meet these goals and build sustainable local capacity, PEPFAR will support training of at 
least 140,000 new health care workers in HIV/AIDS prevention, treatment, and care. PEPFAR works with host nations 
to build capacity in-country; 87 percent of partners are indigenous organizations.
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Congressional Black Caucus (CBC)—$7.3M Transfer from  
Health and Human Services
Referred to as the Minority AIDS Initiative since 2001, this funding is used to support programs that aim to reduce  
HIV among minority populations by focusing on high risk individuals in high prevalence settings. In FY 2008,  
CDC awarded money, through grants and contracts, to several programs seeking to prevent HIV/AIDS in African 
American and other racial and ethnic populations. A sample of some of the programs includes: development of a tool 
to target African American heterosexuals at risk; the African American Men’s HIV Testing Campaign; and an assessment 
of the determinants of HIV risk factors for African American and Hispanic women at risk for HIV infection in the 
Southern United States.
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Infectious Diseases FY2008 Budget Breakdown 
The Infectious Disease line item of the CDC appropriations was $1.9B for FY2008. The Coordinating Center for 
Infectious Diseases (CCID) coordinates and manages this budget line. CCID integrates science, epidemiology and 
laboratory programs, while focusing on cross-organizational activities that increase efficiency and service. Continued 
coordination ensures that infectious disease programs are based on the highest standards of quality, equity, and 
integrity, as well as ensuring excellent service to CDC’s customers. 
CDC’s Infectious Disease activities include responsibility for:
z Investigating infectious disease outbreaks;
z Enhancing preparedness for infectious disease-prone areas/or infectious disease events, such as pandemic 
influenza, by building epidemiology and laboratory capacity;
z Developing domestic and global capacity for recognizing and responding to infectious diseases and protecting the 
health of Americans at home and abroad;
z Developing, implementing, and evaluating effective science-based infectious disease prevention programs in areas 
such as HIV/AIDS, sexually transmitted diseases and tuberculosis;
z Conducting surveillance activities to track infectious diseases and understand their public health dynamics;
z Evaluating surveillance findings for program planning and public health response;
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z Preventing disease, disability, and death in children, adolescents, and adults through safe and effective vaccination;
z Providing technical, epidemiological, educational, statistical and scientific assistance to state and local health 
departments concerning infectious diseases; and
z Developing high quality research and translating relevant findings into infectious diseases prevention policy and 
programs.
The Infectious Disease activities above are carried out by the four National Centers specializing in particular issues 
and areas of expertise, as described in the previous sections. These Centers operate within the Coordinating Center for 
Infectious Diseases (CCID). The budgets to accomplish these tasks are dedicated to four functional areas: 1) vaccine 
preventable diseases; 2) routes of disease transmission; 3) sexually transmitted diseases, and 4) preparedness and 
response functions. The specific budget categories with Infectious Diseases are:
z Immunization and Respiratory Diseases
z Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), Viral Hepatitis, Sexually 
Transmitted Diseases (STDs), and Tuberculosis (TB) Prevention;
z Zoonotic, Vector-Borne, and Enteric Diseases, and
z Preparedness, Detection and Control of Infectious Diseases.
Extramural Funding—Funds Awarded To External Entities
CCID spends 13 percent of the funding it receives to cover the internal infrastructure and personnel. This “Intramural” 
funding is used to support research and epidemiological work done in CDC laboratories, surveillance activities, and 
provides resources for on-site epidemiological assistance when outbreaks occur. 
CCID’s remaining funding (87%) is used to support a wide variety of public health programs and activities externally, 
including, but not limited to: state and local public health departments, academic institutions, research, community 
activities, and vaccine purchases. 
Every state and each US territory, receives funding from CCID to support their local public health departments. In 
addition, CCID also directly funds initiatives in several major metropolitan areas, including Baltimore, Chicago, 
Houston, New York City and Philadelphia. 
CCID also funds numerous international public health programs and collaborates with foreign public health 
departments and universities as we strive to improve public health throughout the world. A list of these entities is 
included as an Appendix.
Funding a variety of programs through grants, cooperative agreements, contracts, interagency agreements, and 
other mechanisms allows CCID to assist with a myriad of cutting edge research projects, outreach and development 
programs that work collectively to expand the nation’s and the world’s health.
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Funding to States and Territories
Much of the CCID annual budget is used to support state and local public health departments. CCID is aware of how 
crucial cooperation and collaboration between the CDC and its state and local partners is to the success of public 
health measures. CDC depends on these partners to report unusual numbers of cases of various disease types, as well 
as unusual pathogens. CCID allocated about one-third, over $737 million, of its FY2008 budget to supporting our 
partners in the state and local health departments.
Supporting Colleges and Universities
CCID is especially proud of the work it does funding and fostering relationships between CDC, the national centers and 
various institutions of higher learning throughout the country. CCID provides almost $370 Million to 56 Colleges and 
Universities to further their research. 
More detailed information regarding CDC’s budget can be found at:  
http://www.cdc.gov/fmo/Budget
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CDC Advisors  
On Infectious Diseases
CDC and the Infectious Diseases areas depend on a number of advisory committees and organizations to provide 
important information and direction on a myriad of public health issues. Their members include those positioned on 
the forefront of the efforts to combat infectious diseases, whether they are public health officers, private practitioners, 
or academicians in areas of cutting edge surveillance and research. 
Board of Scientific Counselors
Mission/Charge: The Board of Scientific Counselors, Coordinating Center for Infectious Diseases, shall advise the 
Secretary, HHS and the Director, CDC, concerning strategies and goals for the programs and research within the 
national centers; shall conduct peer-review of scientific programs; and monitor the overall strategic direction and 
focus of the national centers. The board, after conducting its periodic review, shall submit a written description of the 
results of the review and its recommendations to the Director, CDC. The board shall perform second-level peer review 
of applications for grants-in-aid for research and research training activities, cooperative agreements, and research 
contract proposals relating to the broad areas within the national centers. 
CHAIR 
Richard James WHITLEY, M.D. 
Loeb Eminent Scholar Chair in Pediatrics 
Professor of Pediatrics, Microbiology, Medicine and 
Neurosurgery 
Director, University of Alabama Center For Biodefense 
and Emerging Infections
EXECUTIVE SECRETARY
Janet NICHOLSON, Ph.D. 
Senior Advisor for Laboratory Science 
Coordinating Center for Infectious Diseases 
Centers for Disease Control and Prevention
MEMBERSHIP
Barry J. BEATY, Ph.D. 
Professor, Department of Microbiology, Immunology and 
Pathology  
Colorado State University, 
Gail A. BOLAN, M.D. 
Chief, STD Control Branch 
California Department of Health Services 
Department of Health Services
Matthew L. BOULTON,, M.D., M.P.H. 
Director, Office of Public Health 
School of Public Health 
University of Michigan
Franklin R. COCKERILL III, M.D. 
President and CEO 
Mayo Collaborative Services
H. Dele DAVIES, M.D. 
Professor and Chair 
Department of Pediatrics and Human Development 
Michigan State University 
College of Human Medicine
Jeffrey DAVIS, M.D. 
Chief Medical Officer  
State Epidemiologist for Communicable Diseases 
Division of Public Health 
Wisconsin Department of Health and Family Services
Ralph J. DICLEMENTE, Ph.D. 
Professor of Public Health 
Department of Behavioral Sciences and Health Education 
Rollins School of Public Health 
Emory University
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Ralph GONZALES, M.D., M.S.P.H. 
Associate Professor of Medicine 
Division of General Internal Medicine 
University of California, San Francisco
James HADLER, M.D., M.P.H. 
Public Health Consultant 
Samuel Lawrence KATZ, M.D. 
Wilburt C. Davison Professor Emeritus of Pediatrics 
Children’s Health Center 
Duke University Medical Center
Samuel Lawrence KATZ, M.D. 
Wilburt C. Davison Professor Emeritus of Pediatrics 
Children’s Health Center 
Duke University Medical Center
Marcelle LAYTON, M.D. 
Director, Public Health Practices 
Assistant Commissioner of Health 
Bureau of Communicable Disease 
New York City Department of Health and Mental Hygiene 
Ronald E. STALL, Ph.D., M.P.H.  
Professor, Department of Behavioral and Community 
Health Sciences 
University of Pittsburgh
Robert Bradfield TESH, M.D. 
Professor of Pathology, Microbiology, and Immunology 
Center for Biodefense and Emerging Infectious Diseases 
Department of Pathology 
University of Texas Medical Branch
Robert A. WEINSTEIN, M.D. 
Interim Chairman, Department of Medicine 
John H. Stroger, Jr. (Cook County) Hospital
Mary Elizabeth WILSON, M.D. 
Associate Professor of Medicine 
Harvard Medical School
AD HOC CONSULTANTS AND REVIEWERS
Julio SOTELO, M.D. 
General Director 
National Institute of Health 
Mexico Ministry of Health
John E. BENNETT, M.D. 
Head, Clinical Mycology Section 
Laboratory of Clinical Infectious Diseases and Infectious 
Disease 
Training Program Director 
National Institute of Allergy and Infectious Diseases 
National Institutes of Health
Danielle GRONDIN  
Acting Assistant Deputy Minister 
Infectious Disease and Emergency Preparedness Branch
Michael E. FLEENOR, M.D., M.P.H. F.A.C.P. (ACET) 
Health Officer 
Jefferson County Department of Health
Jesse L. GOODMAN, M.D., M.P.H. 
Director, Center for Biologics Evaluation and Research 
Food and Drug Administration 
Larry M. GRANGER, D.V.M. 
Director, Centers for Epidemiology and Animal Health 
U.S. Department of Agriculture 
Carole HEILMAN, Ph.D.  
Director, Division of Microbiology and Infectious Diseases 
National Institute of Allergy and Infectious Diseases 
National Institute of Health
Edward W. HOOK, III, M.D. (CHAC) 
Professor of Medicine, Microbiology and Epidemiology 
University of Alabama at Birmingham
Duane R. HOSPENTHAL, M.D., Ph.D. 
Chief, Infectious Diseases Service 
Brooke Army Medical Center
Dale MORSE, M.D. (ACIP) 
Director, New York State Health Department
Elissa PASSIMENT, EdM, CLS 
(NCA) (CLIAC) 
Executive Vice President, American Society for Clinical 
Laboratory Science
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Advisory Committee on Immunization Practices (ACIP) 
The Advisory Committee on Immunization Practices provides advice and guidance to the Director of CDC and the Secretary of HHS 
regarding the most appropriate selection of vaccines and related agents for effective control of vaccine-preventable diseases in 
the civilian population. ACIP meets three times each year. When making its recommendations, ACIP considers a number of factors, 
including a review of the evidence of safety, efficacy, effectiveness and cost effectiveness of the vaccine; morbidity and mortality 
associated with the disease; and the feasibility of vaccine use in existing immunization programs. ACIP recommendations provide 
standards of practice, but the ACIP does not have the authority to mandate vaccinations. CDC is committed to fully complying with 
the spirit and technical requirements of the conflict of interest provisions of the Federal Advisory Committee Act.
CHAIRMAN
Dale L. MORSE, M.D., M.S. Assistant Commissioner, Office 
of Science New York State Department of Health
EXECUTIVE SECRETARY
Larry K. PICKERING, M.D. Senior Advisor to the Director 
National Center for Immunization & Respiratory Diseases 
Centers for Disease Control & Prevention 
MEMBERS
Carol BAKER, M.D. Professor of Pediatrics Molecular 
Virology and Microbiology Baylor College of Medicine
Robert L. BECK, J.D. 
Consumer Representative, Palmyra, Virginia
Lance CHILTON, M.D. 
General Pediatrics and Adolescent Medicine, Young 
Children’s Health Center 
Professor, Department of Pediatrics 
University of New Mexico School of Medicine
Paul CIESLAK, M.D. 
Medical Director, Immunization Program& 
Program Manager, Acute & Communicable Disease 
Prevention 
Oregon Public Health Division 
Kristen EHRESMANN, R.N., M.P.H., 
Section Chief 
Immunization, Tuberculosis, and International Health 
Section, Minnesota Department of Health
Janet ENGLUND, M.D. 
Associate Professor of Pediatrics, University of 
Washington 
Clinical Associate, Fred Hutchinson Cancer Research Center 
Division of Infectious Disease, Immunology and 
Rheumatology 
Children’s Hospital and Regional Medical Center
Franklyn N. JUDSON, M.D. 
Professor, Departments of Medicine (Infectious Diseases) 
& Preventive Medicine and Biometrics 
University of Colorado Health Sciences Center
Susan M. LETT, M.D., M.P.H. 
Medical Director, Immunization Program 
Division of Epidemiology and Immunization 
Massachusetts Department of Public Health 
S. Michael MARCY, M.D.  
UCLA Center for Vaccine Research 
Harbor-UCLA Medical Center
H. Cody MEISSNER, M.D. 
Professor of Pediatrics, Tufts Medical Center
Kathleen NEUZIL, M.D., M.P.H.  
Senior Clinical Advisor, PATH 
Clinical Associate Professor of Medicine,  
University of Washington
Mark H. SAWYER, M.D. 
Professor of Clinical Pediatrics 
Division of Pediatric Infectious Disease 
UCSD School of Medicine and Rady Children’s Hospital 
San Diego 
Medical Director, San Diego Immunization Partnership 
San Diego County HHSA Immunization Branch
Ciro Valent SUMAYA, M.D., M.P.H.T.M. 
Founding Dean and Cox Endowed Chair in Medicine 
School of Rural Public Health 
Texas A&M Health Science Center
Jonathan TEMTE, M.D. Ph.D. 
Associate Professor 
Department of Family Medicine 
University of Wisconsin School of  
Medicine and Public Health
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EX OFFICIO MEMBERS
Centers for Medicare and Medicaid Services (CMS) 
Linda MURPHY CAPT, USPHS Senior Health Insurance 
Specialist Centers for Medicare & Medicaid Services
Department of Defense (DOD)  
Wayne HACHEY, DO, M.P.H. LTC, USA, MC Director, 
Preventive Medicine & Surveillance Office of the 
Assistant Secretary of Defense Force Health Protection 
and Readiness 
Theodore (Ted) CIESLAK, M.D. Col, MC Defense 
Department Liaison Officer Centers for Disease Control 
and Prevention
Department of Veterans Affairs (DVA)  
Linda S. KINSINGER, MD, MPH 
Chief Consultant for Preventive Medicine 
Office of Patient Care Services 
National Center for Health Promotion and Disease 
Prevention 
Food and Drug Administration (FDA)  
Norman BAYLOR, Ph.D. Director, Office of Vaccines 
Research Review 
Health Resources & Services Administration (HRSA) 
Geoffrey EVANS, M.D. Director Division of Vaccine Injury 
Compensation 
Rosemary JOHANN-LIANG, M.D. Chief Medical Officer 
National Vaccine Injury Compensation Program 
Indian Health Service (IHS) 
James CHEEK, M.D., M.P.H. 
Director, Division of Epidemiology and Prevention
National Vaccine Program Office (NVPO) 
Bruce GELLIN, M.D., M.P.H. 
Director , National Vaccine Program Office 
National Institutes of Health (NIH) 
George T. CURLIN, M.D. 
Medical Director DMID/NIH 
LIAISON REPRESENTATIVES 
American Academy of Family Physicians (AAFP)  
Doug CAMPOS-OUTCALT, M.D., M.P.A. 
Associate Head  
Department of Family & Community Medicine  
University of Arizona College of Medicine 
American Academy of Pediatrics (AAP) 
Chair, Committee on Infectious Diseases  
Joseph A. BOCCHINI, Jr., M.D. 
LSU Health Sciences Center in Shreveport  
Children’s Hospital of LSU 
Red Book Associate Editor  
David KIMBERLIN, M.D., FAAP  
University of Alabama at Birmingham  
Division of Pediatric Infectious Diseases 
American College Health Association (ACHA) 
James C. TURNER, M.D.  
Executive Director  
Department of Student Health 
Professor of Internal Medicine 
University of Virginia Elson Student Health Center 
American College of Obstetricians & Gynecologists 
(ACOG) 
Stanley GALL, M.D. 
Department of OB/GYN  
University of Louisville School of Medicine 
American College of Physicians (ACP) 
Gregory A. POLAND, M.D. 
Professor of Medicine, Infectious Diseases 
Molecular Pharmacology and Experimental 
Therapeutics and Pediatrics 
Mayo Medical School
American Geriatrics Society (AGS) 
Kenneth SCHMADER, M.D. 
Chief, Division of Geriatrics 
Duke University Medical Center
America’s Health Insurance Plans (AHIP) 
Tamara LEWIS, M.D., M.P.H. 
Medical Director, Community Health and Prevention 
Intermountain Healthcare
American Medical Association (AMA) 
Litjen TAN, M.S., Ph.D. 
Director, Medicine and Public Health 
Chicago, Illinois 
American Osteopathic Association (AOA) 
Stanley E. GROGG, D.O. 
Professor of Pediatrics Oklahoma State University 
Medical Director of Clinical Research 
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American Pharmacists Association (APhA)  
Stephan L. FOSTER, Pharm.D. 
Professor and Vice Chair  
CAPT (Ret) USPHS University of Tennessee  
College of Pharmacy  
Department of Clinical Pharmacy 
Association for Prevention Teaching and Research (APTR) 
W. Paul McKINNEY, M.D. 
Professor & Associate Dean 
School of Public Health and Information Sciences 
University of Louisville K-Bldg 
Washington, DC
Biotechnology Industry Organization (BIO) 
Clement LEWIN, Ph.D., MBA 
Head, Strategic Immunization Planning 
Novartis Vaccines and Diagnostics
Council of State and Territorial Epidemiologists (CSTE) 
Christine HAHN, M.D. 
State Epidemiologist, Division of Health  
Idaho Department of Health and Welfare 
Canadian National Advisory Committee on  
Immunization (NACI) 
Joanne LANGLEY, M.D., MSc, FRCPC 
Professor of Pediatrics (Infectious Diseases) 
Canadian Center for Vaccinology 
Department of Health, United Kingdom  
David M. SALISBURY, CB, FRCP, FRCPCH, FFPH  
Director of Immunization 
Department of Health 
Healthcare Infection Control Practices Advisory 
Committee (HICPAC) 
Steve GORDON, M.D. 
Cleveland Clinic , Department of Infectious Diseases 
Infectious Diseases Society of America (IDSA) 
Samuel L. KATZ, M.D. 
W C Davison Professor and Chair Emeritus  
Duke University Medical Center 
National Association of County and  
City Health Officials (NACCHO) 
Jeffrey S. DUCHIN, M.D. 
Chief, Communication Disease Epidemiology & 
Immunization Section  
Public Health—Seattle & King County  
Associate Professor in Medicine, Division of Infectious 
Diseases, University of Washington 
National Association of Pediatric Nurse Practitioners 
(NAPNAP) 
Patricia STINCHFIELD, NP 
Director Pediatric Infectious Disease & Immunology 
Children’s Hospitals and Clinics of Minnesota 
National Foundation for Infectious Diseases (NFID 
William SCHAFFNER, M.D. 
Professor and Chair 
Department of Preventive Medicine 
Vanderbilt University School of Medicine
National Immunization Council and Child Health 
Program, Mexico (NIACCHO) 
Vesta RICHARDSON, M.D. 
General Director 
National Center for Health of Infancy and Adolescence 
National Medical Association (NMA) 
Patricia WHITLEY-WILLIAMS, M.D. 
Professor of Pediatrics 
Chief, Pediatric Infectious Diseases 
UMDNJ-/Robert Wood Johnson Medical School
National Vaccine Advisory Committee (NVAC) 
Guthrie S. BIRKHEAD, M.D., M.P.H. 
Deputy Commissioner Office of Public Health 
New York State Department of Health
Pharmaceutical Research and Manufacturers of America 
(PhRMA) 
Damian A. BRAGA, President, Sanofi Pasteur 
Peter PARADISO, Ph.D. 
Vice President, New Business/Scientific Affairs  
Wyeth Vaccines 
Society for Adolescent Medicine (SAM) 
Amy B. MIDDLEMAN, M.D., M.P.H., M.S.Ed. 
Associate Professor of Pediatrics  
Baylor College of Medicine  
Adolescent Medicine and Sports Medicine Section 
Society for Healthcare Epidemiology of America (SHEA) 
Harry L. KEYSERLING, M.D. 
Professor of Pediatrics, Division of Infectious Diseases, 
Epidemiology and Immunology, Emory University School 
of Medicine, Department of Pediatrics 
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Advisory Council for the Elimination of Tuberculosis (ACET)
The Advisory Council for the Elimination of Tuberculosis shall provide advice and recommendations regarding the 
elimination of tuberculosis to the Secretary, HHS, the Assistant Secretary for Health, and the Director, CDC. The council 
shall make recommendations regarding policies, strategies, objectives, and priorities; address the development and 
application of new technologies; provide guidance and review on CDC’s Tuberculosis Prevention Research portfolio and 
program priorities; and review the extent to which progress has been made toward eliminating tuberculosis. 
CHAIR
Michael E. FLEENOR, M.D., M.P.H. 
Health Officer 
Jefferson County Department of Health
EXECUTIVE SECRETARY
Hazel D. DEAN, Sc.D., M.P.H. 
Deputy Director  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention 
Coordinating Center for Infectious Diseases 
Centers for Disease Control & Prevention
MEMBERSHIP
Iram BAKHTAWAR, MBBS, MPH 
State Tuberculosis Control Officer 
Arkansas Department of Health
William J. BURMAN, M.D. 
Medical Director 
Infectious Diseases Clinic 
Denver Public Health
Christine HAHN, M.D. 
State Epidemiologist 
Idaho Department of Health and Welfare
Shannon JONES, III  
Assistant Director of Public Health and Community 
Services 
City of Austin/Travis County Texas Health Human Services 
Department
Joseph Clayton KINNEY 
Program Consultant 
Tuberculosis Control Division 
South Carolina Department of Health and Environmental 
Control
Ana A. LOPEZ-DE FEDE, Ph.D. 
Director, Division of Health and Family Studies 
University of South Carolina 
Institute for Families in Society
Masahiro NARITA, M.D., FCCP 
Director, TB Control Program 
Public Health-Seattle and King County 
Associate Professor, Division of Pulmonary and Critical 
Care, University of Washington
Barbara J. SEAWORTH, M.D. 
Medical Director 
Tuberculosis Education Center 
Texas Center for Infectious Disease 
Texas Department of State Health Services
Sirlura TAYLOR, PHN 
Retired – Tuberculosis Program Manager  
Contra Costa Public Health 
EX OFFICIO MEMBERS
Naomi ARONSON, M.D. 
Director, Infectious Disease Division 
Department of Defense, Uniformed Services University of 
the Health Sciences
William B. BAINE, M.D. 
Senior Medical Advisor 
Center for Outcomes and Evidence 
Agency for Healthcare Research and Quality
Amy S. BLOOM, M.D. 
U.S. Agency for International Development 
BGH/OHIV/TLRD
James E. CHEEK, M.D. 
Indian Health Services  
Epidemiology Branch
Caroline FREEMAN 
N3718- US DOL/OSHA 
Director, Office of Biological Hazards
Garth GRAHAM, M.D. 
Director, Office of Minority Health/OS  
Department of Health & Human Services
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Mamodikoe MAKHENE, M.D., MPH 
Medical Officer  
TB and other Mycobacterial Diseases Section, Respiratory 
Diseases Branch 
Division of Microbiology and Infectious Diseases, 
National Institute of Allergy and Infectious Diseases 
National Institutes of Health
Sheldon MORRIS, M.D. 
Food & Drug Administration 
Center for Biological Evaluation & Research
Gary A. ROSELLE, M.D. 
Program Director for Infectious Diseases 
Department of Veteran Affairs
Diana SCHNEIDER, Dr. P.H., M.A. 
Senior Epidemiologist 
US Public Health Service 
Division of Immigration Health Services
Ulonda SHAMWELL 
Acting Associate Administrator 
Substance Abuse & Mental Health Services 
Administration (SAMHSA)
Theresa WATKINS-BRYANT, M.D. 
F.A.A.P., Senior Medical Advisor 
CAPT, US Public Health Service 
Office of Minority Health and Health Disparities/HRSA
David WEISSMAN, M.D. 
Acting Director, Division of Respiratory Disease Studies 
National Institute for Occupational Safety and Health 
LIAISON REPRESENTATIVES
Edward P. DESMOND, Ph.D. 
Association of Public Health Laboratories 
Chief, Mycobacteriology and Mycology Section  
Microbial Diseases Laboratory  
California Department of Public Health
Fran DU MELLE, M.S. 
American Thoracic Society 
Senior Vice President 
Consultant, International Health
Jeffrey P ENGEL., M.D. 
Hospital Infection Control Practices Advisory Committee 
State Epidemiologist and Branch Head 
General Communicable Disease Control Division of Public 
Health, DHHS
Joe GOLDENSON, M.D., FSCP 
Director/Medical Director 
Jail Health Services
Fred GORDIN, M.D. 
American Thoracic Society 
Chief, Infectious Diseases
Phil GRIFFIN, BBA 
President, National Tuberculosis Controllers Association  
Director, Kansas Tuberculosis Prevention & Control and 
Hepatitis C Programs 
Bureau of Disease Control and Prevention 
Robert J. KIM-FARLEY, M.D., M.P.H. 
National Association of County and City Health Officials 
Director, Communicable Disease Control and Prevention 
Department of Public Health, County of Los Angeles 
Michael K. LEONARD, Jr., M.D. 
Infectious Disease Society of America 
Assistant Professor of Medicine 
Division of Infectious Diseases 
Emory University School of Medicine
Edward A. NARDELL, M.D. 
International Union Against Tuberculosis and Lung 
Disease 
Division of Social Medicine and Health Inequalities  
Brigham and Women’s Hospital
Sue PEREZ, M.P.H. 
Federal Policy Director 
Treatment Action Group (TAG)
Dan REYNA, M.S.S., M.P.A. 
General Manager, U.S. Section 
U.S.-Mexico Border Health Commission 
Office of Global Health Affairs 
Office of the Secretary 
Department of Health and Human Services
Lee B. REICHMAN, M.D., M.P.H., FACP, FCCP 
Liaison, American College of Chest Physicians 
Professor of Medicine, Preventive Medicine and 
Community Health 
New Jersey Medical School  
Global Tuberculosis Institute
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Clemente VILLALPANDO PADILLA 
Seretario Ejecutiv, Seccion México 
Comisión de Salud Fronteriza México-Estados Unidos
Rachel L. STRICOF, M.P.H. 
APIC Liaison 
New York State Department of Health
Litjen TAN, Ph.D. 
Director Infectious Diseases, Immunology and Molecular 
Medicine 
American Medical Association 
Medicine & Public Health
Michael L. TAPPER, M.D. 
Society for Healthcare Epidemiology of America
Lornel G. TOMPKINS, M.D. 




Office of Minority Health/OS 
Department of Health and Human Services
HICPAC Liaison
Rachel L. STRICOF, M.P.H. 
HICPAC Liaison 
New York State Department of Health
CDC STAFF
Margie SCOTT-CSEH 
Committee Management Specialist 
CCID, Strategic Business Unit  
Centers for Disease Control & Prevention 
CDC/HRSA Advisory Committee on HIV and  
STD Prevention and Treatment (CHAC)
The CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment advises the Director, CDC, and the 
Administrator and Associate Administrator for HIV/AIDS, HRSA, regarding objectives, strategies, policies, and priorities 
for HIV and STD prevention and treatment efforts including surveillance of HIV infection, AIDS, STDs, and related 
behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS and STDs; identification of 
policy issues related to HIV/STD professional education, patient healthcare delivery, and prevention services; agency 
policies about prevention of HIV/AIDS and other STDs, treatment, healthcare delivery, and research and training; 
strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment 
services; programmatic efforts to prevent and treat HIV and STDs; and support to the agencies in their development of 
responses to emerging health needs related to HIV and other STDs.
CHAIRMAN
Edward W. HOOK, III, MD 
Professor of Medicine 
University of Alabama at Birmingham
DESIGNATED FEDERAL OFFICIALS
Kevin FENTON, MD, PhD  
Director, National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention 
Centers for Disease Control & Prevention
MEMBERS
Bruce D. AGINS, MD, MPH 
Medcial Director, AIDS Institute 
New York State Department of Health
William CUNNINGHAM, MD, MPH 
Department of Health Services 
UCLA School of Public Health
Donna SWEET, MD 
Professor of Medicine 
Dept. of Internal Medicine 
Kansas University School of Medicine - Wichita
Betty James DUKE, PhD 
Administrator, Health Resources and Services 
Administration 
HIV/AIDS Bureau
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Carlos DELRIO, MD 
Professor of Medicine 
Division of Infectious Diseases 
Emory University School of Medicine
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CCID Provides Funding  
to the Following International Organizations and Universities
ACONDA—COTE D’IVOIRE 
Expansion of HIV/AIDS Comprehensive Care & Treatment 
ADDIS ABABA CITY COUNCIL HIV/AIDS 
Development of Model Voluntary Counseling & Testing Services
ADDIS ABABA UNIVERSITY 
Strengthening HIV/AIDS, STI & TB Prevention, Control &  
Treatment Activities
AFRICAN INSTITUTE OF BIOMEDICAL SCIENCE & TECHNOLOGY 
AIBST Capacity Building Project for Training Private  
Health Care Professional
AIDS INFORMATION CENTRE – UGANDA 
Tuberculosis/HIV Integration Activities under PEPFAR
AIDS PREVENTION INITIATIVE IN NIGERIA 
Implementation of Programs for Prevention, Care and Treatment  
of HIV/AIDS
AIDS SUPPORT ORGANIZATION—UGANDA 
Strengthening HIV/AIDS, STI 7 TB Prevention, Control & 
Treatment Activities
ALLIANCE NATIONALE CONTRE LE SIDA—COTE D’IVOIRE 
Expansion of Community-Led, Age-Appropriate HIV/AIDS  
Prevention & Care
ANADER—COTE D’IVOIRE 
Rapid Expansion of Access to HIV/AIDS PCT INT among  
Rural & Other Populations
ARMENIA MINISTRY OF HEALTH 
Surveillance/Response to Avian/Pandemic Influenza by the Sea Hygiene/
Anti-Epidemiology
ASDAP 
Proposal for Screening & Treatment for Sexually Transmitted Infections
AURUM INSTITUTE FOR HEALTH RESEARCH—SOUTH AFRICA 
Inter-Agency PEPFAR Annual Program Statement,  
US Government Mission 
Strengthening Workplace Interventions in SMME’s
BAPTIST AIDS RESPONSE AGENCY IN AFRICA—KENYA 
The New Partner Initiative (NPI) Created under PEPFAR
BAYLOR COLLEGE OF MEDICINE CHILDREN’S FOUNDATION-UGANDA 
Expansion of National Pediatric HIV/AIDS Prevention, Care and Treatment 
BLOOD TRANSFUSION SERVICE OF NAMIBIA 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
BOTSWANA MINISTRY OF HEALTH 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
BUGANDO MEDICAL CENTRE & UNIVERSITY COLLEGE 
Enhancement of a Continuum of HIV/AIDS PCT through Network
CARIBBEAN COALITION/NATIONAL AIDS PROGRAM COORDINATION—
TRINIDAD/TOBAGO 
National AIDS Program
CARIBBEAN COMMUNITY (CARICOM)—GUYANA 
Program on Coordination and Harmonization of HIV/AIDS Activities
CARIBBEAN HEALTH RESEARCH COUNCIL—TRINIDAD/TOBAGO 
Building National monitoring & Evaluation Capacity in the Caribbean 
CATHOLIC MEDICAL MISSION BOARD, INC (CMMB)—SOUTH AFRICA 
Men Taking Action 
CENTRAL STATISTICAL OFFICE—ZAMBIA 
Sample Vital Registration with Verbal Autopsy
CENTRE-ZIMBABWE 
The Support for Civil-Society Organizations that are  
Responding to HIV/AIDS
CHEST DISEASES LABORATORY—ZAMBIA 
Expansion of Reference Laboratory Infrastructure to Support  
HIV/AIDS/STD/TB
CHILD IN NEED INSTITUTE (CINI)—INDIA 
Strengthening Management Support Services for CDC’s  
Global Aids Program in India
CHURCHES HEALTH ASSOCIATION OF ZAMBIA 
Enhancing the Community Response to HIV/AIDS and TB
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COLLEGE OF HEALTH SCIENCES UNIVERSITY OF ZIMBABWE 
Strengthening the Masters-Level Public Health Training Programs 
COLLEGE OF HEALTH SCIENCES, UNIVERSITY OF ZIMBABWE 
Improving Quality of HIV/AIDS Care under PEPFAR
COTE D’IVOIRE MINSTRY/FIGHT AGAINST AIDS 
Reinforcement of the Coordinating Role for the Ivorian Ministry for the 
Fight against AIDS
COTE D’IVOIRE MINSTRY/SOLIDARITY, SOC AF 
Rapid Expansion of the Capacity of the Ministry of Solidarity
DEVELOPMENT AID FROM PEOPLE TO PEOPLE—ZAMBIA 
Total Control of the Epidemic: A House-to-House Approach 
Total Control of the Epidemic: A Door-to-Door Approach to  
Strengthen Communities
DIRECTORATE GENERAL/DISEASE CONTROL/ENVIRONMENTAL HEALTH—
INDONESIA 
Surveillance & Response to Avian and Pandemic Influenza
DRUG CONTROL COMMISSION—TANZANIA 
Implementing Comprehensive HIV Prevention Services for  
Injection Drug Users & Others
EASTERN DEANERY AIDS RELIEF PROGRAM—KENYA 
HIV and TB Prevention and Care
EASTERN PROVINCIAL HEALTH OFFICE—ZAMBIA 
Strengthening the Capacity of the Government in HIV/AIDS Diagnoses
EDUCATION LABOUR RELATIONS COUNCIL—SOUTH AFRICA 
HIV/AIDS Prevention Care and Treatment Access Project for  
South African Teachers
ETHIOPIAN HEALTH & NUTRITION RESEARCH INSTITUTE 
Expansion of PEPFAR Activities: Public Health Laboratory Support
ETHIOPIAN MEDICAL ASSOCIATION 
Human Resource Capacity Building to Accelerate Update of  
Anti-Retroviral Therapy
ETHIOPIAN PUBLIC HEALTH ASSOCIATION 
Improving HIV/AIDS/STI/TB Related Public Health  
Practice & Service Delivery
EXCELLENCE COMMUNITY ED WELFARE SCHEME 
Mobile Voluntary Confidential Counseling & Testing of HIV/AIDS, 
Treatment of Opportunistic Infections
FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA 
Comprehensive HIV Prevention, Treatment and Care Program 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
FEDERAL MINISTRY OF HEALTH ETHIOPIA 
Preparedness and Response to Avian and Pandemic Influenza 
Improving HIV/AIDS/TB Prevention & Control Activities
FEDERAL MINISTRY OF HEALTH NIGERIA 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
FEDERAL POLICE COMMISSION OF ETHIOPIA 
Strengthening HIV/AIDS, TB & STI Prevention,  
Control & Treatment Activities
FIOTEC—BRAZIL 
Strengthening the Brazilian National AIDS Program and  
SOUTH Collaboration 
Expansion of HIV/AIDS/STD Monitoring, Evaluation and  
Other Program Support
FOUNDATION FOR REPRODUCTIVE HEALTH/FAMILY EDUCATION—HAITI 
Strengthening and Expanding HIV/AIDS Treatment, Care and  
Support for Prostitutes
FUNDACAO UNIVERSITARIA JOSE BONIFACIO—BRAZIL 
Administrative and Technical Support for HIV Laboratory Activities
GENERAL STATISTICAL OFFICE—VIETNAM 
Capacity Strengthening on Survey Methodologies & Implementation 
Regarding HIV/AIDS
GEORGETOWN PUBLIC HOSPITAL COPORATION—GUYANA 
Creation of a Center of Excellence at the Georgetown  
Public Hospital Corporation 
GHESKIO CENTER—HAITI 
Strengthen and Expand ARV Treatment in HAITI to HIV/AIDS  
Infected Populations
GORGAS MEMORIAL LABORATORY OF TROPICAL/PREVENTATIVE  
MEDICINE—PANAMA 
Strengthening Regional Reference Lab Capacity in Surveillance 
Operational Research
GOVERNMENT OF BOTSWANA MINISTRY/FINANCE/ 
DEVELOPMENT PLANNING 
Increasing Prevention, Care and Treatment of HIV/AIDS
GUYANA MINISTRY OF HEALTH 
Implement Integrated Care and Prevention of HIV/AIDS
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HAITI MINISTRY OF HEALTH 
Building and Strengthening Capacity for the National Plan for the 
Prevention of… 
Building & Strengthening the Development of Haiti’s Central HIV/AIDS 
Quality Assurance 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
HANOI SCHOOL OF PUBLIC HEALTH 
Partnering with Schools of Public Health to Enhance  
Public Health Capacity
HARAMAYA UNIVERSITY—ETHIOPIA 
Strengthening HIV/AIDS Anti-Retroviral Therapy Training and Services
HEALTH SCIENCE ACADEMY (PTY), LTD—SOUTH AFRICA 
Inter-Agency PEPFAR Annual Program Statement for USG
HIVCARE INTERNATIONAL PTY, LTD—SOUTH AFRICA 
Inter-Agency PEPFAR Annual Program Statement
HO CHI MINH CITY AIDS COMMITTEE 
Strengthening and Expanding HIV/AIDS Surveillance, Prevention and Care
HOPE WORLDWIDE—COTE D’IVOIRE 
HIV Prevention and Care Services for Young People
HUMAN SCIENCES RESEARCH COUNCIL—SOUTH AFRICA 
Improve Capacity of an Indigenous Institute to Enhance M&E of HIV/AIDS
IFAKARA HLTH RES/DEVELOPMENT CENTRE 
Comparing Community and Facility Management of Malaria and 
Pneumonia in Tanzania
IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION—KENYA 
HIV Prevention and Care Services for Young People
INDIAN COUNCIL OF MEDICAL RESEARCH 
Development of Influenza Surveillance Networks 
Addressing Emerging Infectious Diseases in the  
Republic of India-Influenza
INDIAN NETWORK/PEOPLE/WITH HIV/AIDS 
Strengthening Indian Network of Positive People 
INFECTIOUS DISEASES INSTITUTE—UGANDA 
Building Capacity for Scaling up HIV/AIDS Services in  
Kibaale and Kiboga Districts
INSTITUT HAITIEN DE L’ENFANCE 
HIV/AIDS Surveillance in VCT/PMTCT Centers 
INSTITUTE FOR YOUTH DEVELOPMENT—SOUTH AFRICA 
ZISA UNCEDO (Bring Help)
INTEGRATED COMMUNITY BASED INITIATIVES—UGANDA 
Provision of Full Access Home-Based Confidential HIV  
Counseling and Testing 
Expanding Uptake for Interventions to Prevent the Transmission of HIV 
from Mother-to-Child
INTERNATIONAL CHILD CARE—HAITI 
Strengthen & Expand ARV Treatment to HIV/AIDS Infected Populations
INTERNATIONAL CENTERTR/DIARRHOEAL DIS RES 
Addressing Emerging Infections in Bangladesh
INTERNATIONAL ORGANIZATION FOR MIGRATION—SWITZERLAND 
Expanding the Overseas Health Assessment of U.S. Bound Refugees 
Improving Overseas Health Assessment and Management of US-Bound 
Refugees
INTERNATIONAL UNION AGAINST/TB LUNG DISEASE—FRANCE 
Improving Effectiveness of TB Prevention and Control Programs in 
Resource Limited…
KAGISO EDUCATIONAL TELEVISION—SOUTH AFRICA 
Improving Uptake of Prevention Mother-to-Child Transmission
KALANGALA DISTRICT LOCAL GOVERNMENT 
Provision of Full-Access Home-Based Confidential HIV  
Counseling & Testing
KENYA AIDS NGOS CONSORTIUM (KANCO) 
HIV Prevention and Care Services for Young People in Kenya
KENYA MEDICAL RESEARCH INSTITUTE (KEMRI) 
KEMRI/CDC Program
KUMI DISTRICT LOCAL GOVERNMENT—UGANDA 
Full-Access Home-Based Confidential Counseling and  
Testing Using Outreach
LEPRA SOCIETY—INDIA 
Strengthening Management Support Services for CDC’s Global AIDS 
Program in India
LIFELINE NORTH WEST MAFIKENG CENTRE—SOUTH AFRICA 
Inter-Agency PEPFAR Annual Program Statement for USG to South Africa
LIGHTHOUSE TRUST—MALAWI 
HIV Care and Treatment Integrated Programs for Comprehensive Care
LIVERPOOL VCT—KENYA 
Voluntary Counseling, HIV Testing and AIDS Care in Stand Alone 
Community Centers
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LUSAKA PROVINCIAL HEALTH OFFICE 
Improving Lab Infrastructure & Systems for the  
Care & Treatment of Patients
MAHIDOL UNIVERSITY-THAILAND 
Avian Influenza Surveillance in Thailand-Studies at  
Human-Animal Interface 
Avian Flu Surveillance Network in Displaced Populations  
on the Thai Burma Border
MAKERERE MEDICAL SCHOOL—UGANDA  
Developing National Capacity for the Management of  
HIV/AIDS Programs and Support 
Provision of Routine HIV Testing, Counseling, Basic Care & Anti-Retrovirals 
Expanding Tuberculosis/HIV Integration Activities 
MAKERERE UNIVERSITY—UGANDA 
Expanding Tuberculosis/HIV Integration Activities
MAKGABANENG—BOTSWANA 
Age-Appropriate Behavior Change Communication through Radio & 
Reinforcement Activities
MALARIA CONSORTIUM 
Monitoring & Evaluation of Malaria Activities in the  
Greater Mekong Subregion U01
MALAWI AIDS COUNSELING & RESOURCE ORGANIZATION 
Malawi HIV Counseling Testing, Training and Mentoring Program 
National Training & Mentoring Program to Strengthen VCT Programs
MALAWI BLOOD TRANSFUSION SERVICE 
Supporting the Provision of a Safe & Adequate supply of  
Blood and Blood Products
MALAWI NATIONAL AIDS COMMISSION 
Coordinate & Implement HIV/AIDS Surveillance, Capacity Building 
Activities to Supplement
MATIBABU FOUNDATION—KENYA 
The New Partner Initiative (NPI) Created under PEPFAR
MC CORD HOSPITAL—SOUTH AFRICA 
McCord/ZOE-LIFE Partnership Implementation of Comprehensive & 
Integrated HIV Care
MEDIA SUPPORT PARTNERSHIP—UNITED KINGDOM 
Program Implementation and Capacity Building Support for a Four 
Component Prevention Strategy
MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA 
Preventing Maternal and Neonatal Bacterial Infections in Developing Settings 
Cooperative Agreement to the Medical Research Council of  
South Africa for TB
MEDICAL UNIVERSITY OF SOUTHERN AFRICA 
University Technical Assistance on Projects Aimed at Expanding the 
Delivery of HIV/AIDS Treatment
MEXICO NATIONAL INSTITUTE OF PUBLIC HEALTH 
Surveillance/Response to Avian Flu/Pandemic Influenza 
MILDMAY INTERNATIONAL—UGANDA 
Expansion of HIV/AIDS Care & Treatment Services and Training Activities
MILDMAY MISSION HOSPITAL—UNITED KINGDOM 
Expansion of HIV/AIDS Care Training Activities in the Republic of Kenya
MINISTRY OF HEALTH AFGHANISTAN 
Surveillance and Response to Avian and Pandemic Influenza
MINISTRY OF HEALTH ANGOLA 
Surveillance and Response to Avian and Pandemic Influenza
MINISTRY OF HEALTH ARGENTINA 
Surveillance and Response to Avian and Pandemic Influenza
MINISTRY OF HEALTH BANGLADESH 
Surveillance & response to Avian and Pandemic Influenza by  
National Health Authority
MINISTRY OF HEALTH KENYA 
Surveillance/Response to Avian/Pandemic Influenza by National Health 
Authorities
MINISTRY OF HEALTH MONGOLIA 
Development of Influenza Surveillance Networks
MINISTRY OF HEALTH MORROCO 
Strengthening Influenza Surveillance Networks in Morocco
MINISTRY OF HEALTH NIGERIA 
Surveillance and Response to Avian and Pandemic Influenza
MINISTRY OF HEALTH PERU 
Support for the Plan of Preparation/Response against a Potential 
Influenza Pandemic
MINISTRY OF HEALTH RWANDA 
Strengthening the Capacity of the Ministry of Health to Respond to the 
HIV/AIDS Epidemic 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
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MINISTRY OF HEALTH UGANDA 
Strengthening HIV/AIDS Prevention, Care, Treatment, Support & Strategic 
Information 
MINISTRY OF HEALTH ZAMBIA 
Support of Government Infrastructure for HIV/AIDS/TB/STD  
Control Activities 
MINISTRY OF HEALTH AND CHILD WELFARE—ZIMBABWE 
Expansion of Surveillance Care & prevention Activities for HIV/AIDS & STIs
MINISTRY OF HEALTH AND PUBLIC HYGIENE—COTE D’IVOIRE 
Build Capacity at the Central 7 Decentralized Level 
Epidemiology and Laboratory Capacity Building for  
Surveillance and Response 
MINISTRY OF HEALTH AND SOCIAL SERVICES—NAMIBIA 
Expansion of Voluntary Counseling & Testing, Prevention of  
Mother-to-Child Transmission
MINISTRY OF HEALTH AND VOCATIONAL—TANZANIA 
Strengthening & Expanding HIV Prevention Education among Primary 
School public Through Life-Planning
MINISTRY OF NATIONAL EDUCATION—COTE D’IVOIRE 
Assisting the Ministry of National Education to Implement a National… 
Rapid Expansion of HIV/AIDS Prevention, Care Treatment
MOZAMBIQUE MINISTRY OF HEALTH 
Implementation of Integrated HIV/AIDS Treatment,  
Care and Prevention Programs 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
MUHIMBILI UNIVERSITY/ ALLIED HEALTH SCIENCES 
Tanzania AIDS Prevention Project: HIV Risk Reduction & Care and 
Treatment of Drug Users
MULLAN AND ASSOCIATES (PTY) 
Building Human Resource Capacity to Support Prevention, Care and 
Treatment Strategies
MYRADA—INDIA 
Strengthening Management Support Services for CDC’s Global AIDS 
Program in India
NAMIBIA INSTITUTE OF PATHOLOGY 
Expansion of HIV/STD and TB Laboratory Activities
NATIONAL AIDS/STI CONTROL PROGRAM—KENYA 
Expanding and Integrating HIV Care in Kenya
NATIONAL BLOOD TRANSFUSION SERVICE— COTE D’IVOIRE 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
NATIONAL BLOOD TRANSFUSION SERVICE—KENYA 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
NATIONAL BLOOD TRANSFUSION SRV, GUYANA 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
NATIONAL CENTER FOR HIV/AIDS/DERMA/STDS—CAMBODIA 
Expanding HIV/AIDS Program Activities of the Ministry of Health 
NATIONAL CENTER/AIDS/STD CONTROL/PREVENTION—CHINA 
Prevention of Secondary Transmission among Most At-Risk Populations
NATIONAL DEPARTMENT OF CORRECTIONAL SERVICES—SOUTH AFRICA 
Program to Reduce the Impact of HIV/AIDS within  
the Correctional Services
NATIONAL HEALTH LABORATORY SERVICE—SOUTH AFRICA 
Expansion of HIV/AIDS/STD and TB Laboratory Activities
NATIONAL HIV/AIDS/STI/TB COUNCIL—ZAMBIA 
Support of Government Infrastructure for HIV/AIDS/STD/TB  
Control Activities
NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES—SOUTH AFRICA 
South African Preparedness for Rapid Detection of Highly Pathogenic 
Avian Influenza 
Expansion of HIV/AIDS, STD & TB Laboratory Activities at NICD 
NATIONAL INSTITUTE OF PUBLIC HEALTH/ENVIRONMETNAL HYGIENE 
(RIVM)-NETHERLANDS 
Avian Influenza CRC-Studies at the Human-Animal Interface
NATIONAL INSTITUTE FOR MEDICAL RESEARCH—TANZANIA 
Enhancement of HIV/AIDS Laboratory Training and Q/A Center 
NATIONAL INSTITUTE HYGIENE/EPIDEMIOLOGY—VIETNAM 
Development of Influenza Surveillance Networks 
Partnering with the NIHE to Enhance Public Health Capacity  
for HIV Prevention 
NATIONAL INSTITUTE OF HEALTH—PAKISTAN 
Development of Influenza Surveillance Networks
NATIONAL INSTITUTE OF HEALTH OF KOREA 
Development of Influenza Surveillance Networks
NATIONAL INSTITUTE OF PUBLIC HEALTH—CAMBODIA 
Improving Laboratory Capacity and Quality for HIV/AIDS  
Programming in the Kingdom
NATIONAL INSTITUTE OF VIRAL DISEASE CONTROL/PREVENTION—CHINA 
Development of Influenza Surveillance Networks
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NATIONAL MEDICAL STORES—UGANDA 
Purchase, Distribution and Tracking of Supplies to Support HIV/AIDS 
Related Treatment
NATIONAL REFERENCE LABORATORY—RWANDA 
Strengthening the Capacity of the Government in HIV/AIDS Diagnoses
NETWORK OF AIDS RESEARCHERS E&S AFRICA—KENYA 
Implementation of Programs for PMTCT through NGOs
POTENTIA NAMIBIA RECRUITMENT CONSULTANCY 
Building human Resource Capacity within the Ministry of Health and 
Social Services
PRINCE LEOPOLD INSTITUTE OF TROPICAL MEDICINE—BELGIUM 
Assessment of Youth Interventions in Asembo and  
Gem Nyanza Province, Kenya
PRO-HEALTH INTERNATIONAL 
Implementation of Programs for Prevention,  
Care and Treatment of HIV/AIDS
PROMOTEURS OBJECTIF ZEROSIDA—HAITI 
Strengthen HIV/AIDS Prevention, Care and Treatment Referral Services 
Targeting MSM
PROTECTING FAMILIES AGAINST AIDS—UGANDA 
Promoting Extensive Implementation of Quality Prevention  
of PMTCT Activities
REACTION CONSULTING (PTY), LTD—SOUTH AFRICA 
Strengthening Public Sector HIV Testing, CARE & Treatment  
Capacity in Mpumalanga
REPUBLIC OF MALAWI MINISTRY OF HEALTH 
Strengthening of Tuberculosis/HIV Services
RESEARCH INSTITUTE FOR TROPICAL MEDICINE 
Development of Influenza Surveillance Networks
ROYAL GOVERNMENT OF CAMBODIA 
Development of Influenza Surveillance Networks Overseas
SACTWU AIDS PROJECT—SOUTH AFRICA 
Rapid Expansion Program of SACTWU AIDS Project
SAKH’ULUTSHA: SU LIFESKILLS EDUCATION—SOUTH AFRICA 
Life Skills Education for Children & Youth Aged 10-18 Years,  
Dealing with Value Based
SANQUIN BLOOD SUPPLY FOUNDATION—NETHERLANDS  
Providing Technical Assistance Support for the  
Rapid Strengthening of Blood
SECRETARIAT OF THE PACIFIC COMMUNITY—NEW CALEDONIA 
Development of Influenza Surveillance Networks
SHARE INDIA 
Strengthening Non-Governmental Organizations and  
Private Sector Care Networks 
Strengthening Management Support Services for CDC’s Global AIDS 
Program in India
SOPHUMELELA CLINIC INC. 
The New Partner Initiative (NPI) Created under PEPFAR
SOUL CITY—SOUTH AFRICA 
Inter-Agency PEPFAR Annual Program Statement 
SOUTH AFRICA DEPARTMENT OF HEALTH 
Expansion of HIV VCT, PMTCT Studies and HIV Surveillance
SOUTH AFRICAN DEMOCRATIC TEACHER’S UNION—SOUTH AFRICA 
HIV & AIDS Prevention and Palliative Care for Teachers, Orphans and 
Vulnerable Populations
SOUTH AFRICAN NATIONAL BLOOD SERVICE 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
SOUTHERN AFRICAN CATHOLIC BISHOPS CONFERENCE 
Catholic Church Response to HIV/AIDS in South Africa; Care, 
 Support & Treatment
SOUTOURA ASSOCIATION—MALI 
Proposal for Screening & Treatment for   
Sexually Transmitted Infections (STIs)
ST. MARY’S CATHOLIC MISSION HOSPITAL TRUST—SOUTH AFRICA 
Activities that Strengthen Services at St. Mary’s Hospital
TAMIL NADU STATE AIDS CONTROL SOCIETY—INDIA 
Strengthen State AIDS Control Society Response to HIV/AIDS
TANZANIA MARKETING AND COMMUNICATION CO 
Engaging Parents in Sexual Risk Prevention Efforts Targeting Youth
TANZANIA MINISTRY OF HEALTH/SOCIAL WELFARE 
Preparedness and Response to Avian and Pandemic Influenza in the 
United Republic of Tanzania,  
Strengthening the Capacity of Tanzania Ministry of Health & Social Welfare 
Increasing the Capacity of the Ministry of Health to Expand Coordinated 
HIV Prevention  
Antenatal Care Service and Blood Safety for  
Preventing Transmission of HIV 
Rapid Strengthening of Blood Transfusion Services in Selected Countries 
Enhancement of Palliative Care TB/HIV Collaboration under PEPFAR
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TANZANIA YOUTH ALLIANCE (TAYOA) 
Promotion HIV Prevention for Youth through a  
National HIV Hotline and BCC
TB CARE ASSOCIATION—SOUTH AFRICA 
Advancing PEPFAR Goals for Increasing Access to HIV/TB  
Diagnosis Care Treatment
TEBELOPELE VOLUNTARY COUNSELING/TESTING CENTER—BOTSWANA  
Expanding and Enhancing HIV Voluntary Counseling and Testing Services
THAILAND MINISTRY OF PUBLIC HEALTH 
Population-Based Surveillance for Emerging Infections in Thailand 
International Emerging Infections Program Surveillance in Thailand 
Development of Influenza Surveillance Networks
THETA LTD—UGANDA 
The New Partner Initiative (NPI) Created under PEPFAR
TMLIVERPOOL SCHOOL OF TROPICAL MEDICINE 
Institutional Collaborating Between Liverpool STM & CDC on Malaria
TOGA/INTEGRATED HIV SOLUTIONS—SOUTH AFRICA 
Togtainer Deployment
TRADITIONAL & MODERN HEALTH PRACTIONERS—UGANDA 
Supporting the National Prevention of HIV Mother-to-Child Transmission
TREATMENT RESEARCH AIDS CENTER (TRAC)—RWANDA 
Preparedness and Response to Avian and Pandemic Influenza  
Strengthening the Capacity of the Government’s Treatment and  
Research for AIDS
TROPICAL DISEASE FOUNDATION—PHILLIPINES 
Improving the Effectiveness of the Diagnosis of TB
TSHEPANG TRUST—SOUTH AFRICA 
Tshepang Trust
UBUNTU EDUCATION FUND—SOUTH AFRICA 
Improving HIV Prevention, Care & Support for Vulnerable  
Populations in the Ibhay
UGANDA BLOOD TRANSFUSION SERVICE 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
UGANDA VIRUS RESEARCH INSTITUTE 
Identification, Surveillance and Control of Vector-Borne and Zoonotic 
Infectious Diseases 
Strengthening National Capacity for Surveillance and Containment of 
Avian and Pandemic Influenza 
Provision of Quality Assurance for HIV 
Randomized Trial of Home or Facility-Based AIDS Care
UNICEF ZAMBIA 
Prevention of Mother to Child Transmission of HIV (PMTCT) &  
Pediatric HIV Care
UNIVERSITY COMPUTING CENTRE LTD—TANZANIA 
Software Development, Support, Training 7 technical Assistance for Care 
& Treatment Clinics
UNIVERSITY OF GONDAR—ETHIOPIA 
Strengthening HIV/AIDS, TB & STD Prevention,  
Control and Treatment Activities
UNIVERSITY OF HONG KONG 
A Controlled Trial of Masks and Hand Hygiene for  
Reducing Influenza Transmission
UNIVERSITY OF KINSHASA 
Surveillance & Response to Avian and Pandemic Influenza  
Strengthening Infectious Disease Control 
UNIVERSITY OF KWAZULU-NATAL—SOUTH AFRICA 
University Technical Assistance Projects for PEPFAR in South Africa 
Caprisa AIDS Treatment Program 
Inter-Agency PEPFAR Annual Program Statement 
UNIVERSITY OF MALAWI 
Strengthening National Capacity in Operations Research  
Fellowship for Leadership in HIV Prevention, Treatment, Care & Support 
Research Studies to reduce Mother-to-Child HIV-1 Transmission
UNIVERSITY OF NAIROBI 
Training for Program Managers of Kenya 
HIV Treatment for Research Subjects or by Researchers 
Capacity Building in the Implementation of a Comprehensive Program to 
Prevent PMTCT
UNIVERSITY OF OTAGO 
Pandemic Influenza Control at the Border of Island Countries and 
 in the Household
UNIVERSITY OF PRETORIA 
Use of Child Healthcare Problem Identification Programs & Perinatal 
Problem Identification
UNIVERSITY OF STELLENBOSCH—SOUTH AFRICA 
Pediatric-TB/HIV PEPFAR
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UNIVERSITY OF THE WESTERN CAPE 
Human Capacity Development to Address HIV/AIDS in South Africa
UNIVERSITY OF ZAMBIA 
Strengthening the Quality and Scope of the MPH Degree
UNIVERSITY TEACHING HOSPITAL—ZAMBIA 
Expansion of Reference Library Infrastructure to  
Support HIV/AIDS/STD/TB 
Implementation of Multi-Disciplinary HIV Care for  
Sexually Abused Children
VIETNAM ADMINISTRATION HIV/AIDS CONTROL 
Strengthening Coordination & Development of HIV/AIDS  
Prevention and Care
VIETNAM MINISTRY OF HEALTH 
Surveillance and Response to Avian and Pandemic Influenza in Vietnam
WALTER SISULU UIVERSITY 
Increase Indigenous Institutional & Human Capacity to  
Provide Quality Care
WESTERN PROVINCIAL HEALTH OFFICE—ZAMBIA 
Improve Management of Care of HIV/AIDS, STIs & TB  
in the Western Province
WORLD HEALTH ORGANIZATION 
Addressing Emerging Infectious Diseases 
Strengthening Avian Influenza Surveillance & Pandemic Influenza 
Preparedness Plan 
Polio Eradication 
Support Services for the HIV/AIDS Pandemic 
Expanding Efforts and Strategies to Prevent and Control of TB and TB/HIV 
Rapid Strengthening of Blood Transfusion Services in Selected Countries 
Cooperative Agreement with the Joint United Nations  
Program on HIV/AIDS
WORLD HEALTH ORGANIZATION SOUTH EAST ASIA 
Proposal for a Cooperative Agreement with the CDC
WORLD HEALTH ORGANIZATION—AFRO 
Enhancing Communicable Diseases Surveillance in the African Region 
Surveillance and Response to Avian and Pandemic Influenza  
by Regional Offices
WORLD HEALTH ORGANIZATION-WEST PACIFIC 
Proposal for a Cooperative Agreement with the CDC
WORLD HEALTH ORGANIZATION-E MEDITERRANEAN OFFICE 
Strengthening Influenza Surveillance (WHO/EMRO)
YOUTH FOR CHRIST SOUTH AFRICA 
HIC/AIDS Prevention Program through the ABC Method
ZAMBIA NATIONAL BLOOD TRANSFUSION SERVICES 
Rapid Strengthening of Blood Transfusion Services in Selected Countries
ZAMBIA TROPICAL DISEASES RESEARCH CENTER 
Expansion of Reference Laboratory Infrastructure to  
Support HIV/AIDS/STD/TB
ZAMBIA-EMORY HIV RESEARCH PROJECT 
Expansion of ZEHRP’s Couples Voluntary Counseling and Testing Services
ZANZIBAR AIDS PROGRAM MINISTRY/HEALTH & SOCIAL SERVICES 
Enhancement of HIV/AIDS Prevention, care and Treatment Services 
ZIMBABWE NATIONAL QUALITY ASSURANCE PROGRAM 




BSC Board of Scientific Counselors
CC/COs Coordinating Centers/Coordinating Offices 
CCID Coordinating Center for Infectious Diseases 
CMO Chief Management Official 
COTPER Coordinating Office of Terrorism Preparedness and Emergency Response
DHQP Division of Healthcare Quality Promotion (in NCPDCID)
EI Emerging Infections
EISOs Epidemic Intelligence Service Officer
ELB Executive Leadership Board 
GAVI  Global Alliance for Vaccines and Immunization 
HPO High Performing Organization
ICU Influenza Coordination Unit
ISO Immunization Safety Office
MoH Ministries of Health
MRSA Methicillin-Resistant Staphylococcus Aureus 
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCZVED National Center for Zoonotic, Vector-Borne, and Enteric Diseases
NCPDCID National Center for Preparedness, Detection, and Control of Infectious Diseases 
NCIRD National Center for Immunization and Respiratory Diseases
OEA Organization Excellence Assessment 
OWCD Office of Workforce and Career Development
PHIBS Public Health Integrated Business Services 
PMT Performance Management Team 
QMS Quality Management System 
SBU Strategic Business Unit
SME Subject Matter Expert
SNS Strategic National Stockpile
SPO Senior Performance Officer 
SSPU Strategic Science and Program Unit
STARLIMS State-of-the-Art Laboratory Information Management Systems
URDO Unexplained Respiratory Disease Outbreak 
VMBIP  Vaccine Management Business Improvement Project 
WHO World Health Organization
XDR TB  Extensively Drug-Resistant Tuberculosis
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